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ABSTRACT 
 
Uterocalin (Lcn2; also called 24p3, SIP24, or siderocalin and abbreviated as Utc) is  
an acute phase protein, for which the physiological function remains to be determined. Basal 
Utc expression is highest in the uterus, mammary gland and lung, which are three tissues 
with direct exposure to the diverse bacterial flora of the external environment. The 
demonstrated ability to bind siderophores is one means by which Utc can provide protection 
against pathogenic bacteria. However, its specificity for siderophores limits the ability of Utc 
to ward off pathogens. Epithelial tissues that interact with the external environment are 
exposed to many different nonpathogenic resident bacteria to which the tissue normally does 
not mount an inflammatory response. We postulate that Utc might limit inflammation by 
suppressing cytokine expression in response to bacterial products such as LPS. To test this 
hypothesis, we studied the effect of LPS, delivered by intranasal administration, in Lcn2-
deficient mice (Lcn2-/-) and their wild type littermates. Utc is highly expressed in the lungs 
of normal mice at 4 h and 48 h after LPS intranasal challenge. By multiplexed and real-time 
RT-PCR we found that 6 h after intranasal administration of LPS (0.4 to 4 mg/kg), the 
expression of TNF-α, IL-1β and IL-6 was increased in Lcn2-/- compared with their wild type 
littermates. H & E immunohistochemical staining of the lung and liver showed that the 
higher dose of LPS (4 mg/kg) caused the entry of some neutrophils into the lungs of Lcn2-/- 
animals and their wild type littermates. No neutrophils were observed in the lung and liver 
from mice treated at the lower doses. The reaction of older Lcn2-/- mice (11 or 14 weeks old) 
in response to the LPS intranasal administration was more dramatic compared with younger 
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mice (7 or 8 weeks old). In summary, our results indicate that Lcn2 may play an anti-
inflammatory role in the lung and liver and provide feedback regulation of the acute phase 
response by suppressing pro-inflammatory cytokine expression. 
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INTRODUCTION 
 
THESIS ORGANIZATION 
My work mainly involves the investigation of the roles of lipocalin 2 (Lcn2) in the  
inflamed lung and liver. My focus is mouse Lcn2, called Uterocalin (Utc). The protein has 
also been called 24p3, SIP24 and siderocalin. In the introduction, I have first introduced the 
lipocalin family, its history and development. Then I have moved on to Lcn2, the target 
molecule of our research. In this section, I have outlined the previous and ongoing research 
of human, mouse, rat and chicken Lcn2 proteins with focus on the first two. Since we are 
studying the role of Lcn2 in inflammation, there is a brief introduction to inflammation and 
several major inflammatory cells, including neutrophils, macrophages, mast cells and 
dendritic cells. Because Utc is demonstrated to be an acute phase protein, a brief introduction 
of acute phase response and acute phase protein follows. Cytokines, the most critical 
inflammatory mediators, are then introduced with the focus on TNF-α, IL-β and IL-6. 
Because LPS is the reagent used to induce inflammation in animals, an introduction of LPS, 
TLR and LPS signaling pathway is also included. This introduction chapter is concluded with 
a brief description of my current studies. Subsequently, the thesis describes the experimental 
materials and methods, followed by results and discussion, conclusions and future directions. 
In another section called Appendix, other work done for the thesis is described. Finally are 
the acknowledgment and references.  
 
 
  
2 
LIPOCALIN FAMILY 
The lipocalin family is a large and diverse protein family. Most of the lipocalins are  
small (usually 160-180 amino acids) secreted proteins, which are characterized by their 
binding capabilities for small hydrophobic molecules, such as retinol and fatty acids (Flower, 
North et al. 2000). Lipocalins are found in various species including vertebrates and 
invertebrates, insects, plants and even bacteria. In the past, the lipocalins were typically 
classified as transport proteins. Now it is realized that the lipocalins have much more diverse 
functions beyond retinol transport, among which, are invertebrate cryptic coloration, steroid, 
odor molecule and pheromone transport, animal behavior regulation and prostaglandin 
synthesis (Flower 1996; Akerstrom, Flower et al. 2000). Some lipocalins have also been 
implicated in the regulation of cell differentiation, proliferation and apoptosis, modulation of 
the immune system, and the involvement in tumor formation, growth, invasion and 
metastasis (Peitsch and Boguski 1991; Flower 1996; Akerstrom, Flower et al. 2000). 
Lipocalins demonstrate great diversity at the amino acid sequence level. The similarity at this 
level is usually less than 20%, which is the threshold to be identified as a protein family. 
However they share a highly conserved tertiary structure, which is comprised of eight anti-
parallel β-sheets forming an internal ligand binding pocket, also called a calyx. Each two β-
sheets are connected by a loop, one 310 helix is attached at the N terminal and a Helix A1 is 
attached at the C terminal. There are three sequence conserved regions (SCRs) present at the 
amino acid sequence level (Figure 1) (Flower, North et al. 2000). Some lipocalins share all 
three SCRs (kernel lipocalins), and some only share one (outlier lipocalins) (Flower 1996; 
Akerstrom, Flower et al. 2000; Flower, North et al. 2000).  Based on the conserved barrel-
like structure, all lipocalins have several common molecular recognition properties: Firstly, 
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they can form covalent or non-covalent complexes with soluble macromolecules, for 
example α1-microglobulin forms a complex with IgA and the human Lcn2, neutrophil 
gelatinase associated lipocalin (NGAL), is linked through a disulfide bond with gelatinase. 
Secondly, they can bind to specific cell surface receptors, for example, lipocalin 1 binds to 
LIMR (Lcn1 interacting membrane receptor), and the first truly specific lipocalin receptor to 
be cloned (Wojnar, Lechner et al. 2001). Thirdly, they can bind to small hydrophobic 
molecules, for example the chicken Lcn2, extracellular fatty acid binding protein (EX-FABP), 
binds preferentially to long chain unsaturated fatty acids (Cancedda, Malpeli et al. 1996). 
Lipocalins are demonstrated to have many potential clinic applications and some of them 
have been extensively used as biomarkers for inflammatory diseases, cancers, lipid disorders, 
liver and kidney dysfunctions (Xu and Venge 2000). For example, α1-microglobulin has 
been used as a clinical marker of renal tubular injury (Grubb 1992; Weber and Verwiebe 
1992). Apolipoprotein D has been used as marker for male breast carcinomas, prostate cancer, 
Alzheimer's disease, inner ear disorder and kidney dysfunction (Lea, Kvinnsland et al. 1987; 
Holmquist, Vesterberg et al. 1993; Thalmann, Kohut et al. 1994; Terrisse, Poirier et al. 1998). 
Retinol-binding protein has been used as a marker for hepatocytic growth, liver regeneration, 
acute liver injury and renal diseases (Guy, Brammah et al. 1997; Horn, Wax et al. 1999). 
Prostaglandin D synthase, the only lipocalin that has been shown to be an enzyme, is a 
potential marker for brain tumors, renal insufficiency and seminal plasma fertility (Peitsch 
and Boguski 1991; Diamandis, Arnett et al. 1999; Melegos, Grass et al. 1999). NGAL, first 
identified as a component of human neutrophil granules, was reported to be particularly 
useful for distinguishing acute bacterial and viral infections with high degree of accuracy, 
sensitivity and specificity (Venge 1994; Xu, Pauksen et al. 1995). NGAL is also suggested 
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for use as a marker of acute pulmonary exacerbations (Eichler, Nilsson et al. 1999). Some 
lipocalins also have protease inhibitory properties such as tear prealbumin, which is a 
cysteine protease inhibitor, and mouse major urinary protein, which is a trypsin inhibitor. 
This protease inhibitory property makes them possible regulators of cancer cell proliferation 
(Wu, Robertson et al. 1999; Bratt 2000). Four human lipocalins have been classified as acute 
phase proteins (APPs). They are α1-acid glycoprotein (Fournier, Medjoubi et al. 2000), α1-
microglobulin (Akerstrom, Logdberg et al. 2000), glycodelin (Halttunen, Kamarainen et al. 
2000) and the complement factor C8 Q-subunit (Schreck, Parker et al. 2000). All four 
proteins are encoded by a cluster of genes in the q32-34 region of chromosome 9 in the 
human genome (Logdberg and Wester 2000). They all show evidence of having protective 
immuno-regulatory, anti-inflammatory or antimicrobial abilities. Based on this finding, Dr. 
Lennart Logdberg suggested to call them immunocalins and this implicates a subset of 
lipocalins might play a very important role in human immune system (Logdberg and Wester 
2000). Utc has been shown to be an acute phase protein in the mouse (Liu and Nilsen-
Hamilton 1995). 
 
LIPOCALIN 2 
NGAL: The human Lipocalin 2 (Lcn2) was first identified as a component of human  
neutrophil granules, so it was named Human Neutrophil Lipocalin (HNL) by one group (Xu, 
Carlson et al. 1994; Xu, Petersson et al. 1994). Very soon, this protein was found to be 
associated with gelatinase in the neutrophil granules through a disulfide bond, and named by 
a second group as Neutrophil Gelatinase Associated Lipocalin (NGAL) (Triebel, Blaser et al. 
1992; Kjeldsen, Johnsen et al. 1993; Kjeldsen, Cowland et al. 2000). Three forms of NGAL 
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are present in cells. One is the 25 kDa monomer, the second is the 46 kDa disulfide-linked 
homodimer, and the third is the 135 kDa disulfide-linked NGAL and gelatinase (also called 
MMP9, matrix metalloproteinase 9) heterodimer (Kjeldsen, Koch et al. 1996; Goetz, Willie 
et al. 2000; Kjeldsen, Cowland et al. 2000; Borregaard and Cowland 2006). NGAL is the 
only lipocalin 2 ortholog that has a free –SH group and 10% of NGAL is found in the form 
of the heterodimer in neutrophil extracts. The first putative ligand identified for NGAL was 
the bacterial tripeptide N-formyl-Met-Leu-Phe (fMLP), a strong neutrophil chemoattractant 
(Allen, Erickson et al. 1989; Sengelov, Boulay et al. 1994). This observation indicated that 
NGAL may have immuno-modulatory effects. During NGAL purification, a fatty acid called 
n-capric acid (NCA) was copurified. But neither the shape of NCA nor its chemical property 
matched the calyx binding pocket of NGAL (Goetz, Willie et al. 2000).  
 
Compared with other lipocalin structures, the NGAL calyx is larger, wider and more  
open (Figure 2A). At the same time, unlike other lipocalins, the inner surface of the binding 
pocket is quite polar and demonstrates an overall positive charge (Goetz, Willie et al. 2000). 
The NGAL calyx is large enough to accommodate macromolecules, such as a small protein. 
This suggests that molecule other than fMLP or NCA a more likely ligand (Goetz, Willie et 
al. 2000). Without knowing the true ligand, the molecular mechanism behind NGAL function 
is still a mystery.  
 
In 2002, two papers were published in the same issue of the same journal and showed  
that NGAL bound tightly to bacterial catecholate-type ferric siderophores with 10-9 
dissociation constant. This would make NGAL a potent bacteriostatic agent under iron-
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limiting conditions. Identification of this ligand was based primarily on X-ray 
crystallography (Goetz, Holmes et al. 2002; Yang, Goetz et al. 2002). The negatively charged 
ferric siderophore and its structure elegantly matched the positively charged NGAL calyx 
(Figure 2B). Siderophores are the strongest iron chelators known so far. They are secreted by 
bacteria under iron-depleted conditions. After being iron-loaded, siderophores are taken up 
by bacteria by way of siderophore transporters such as FhuA and FepA that are located on 
the bacterial outer membrane (Braun and Braun 2002). Iron is then released from the 
internalized siderophores for bacterial use. There are two types of siderophores produced by 
bacteria: one is the hydroxamate-type and the other is the catecholate-type. The catecholate-
type enterobactin exhibits the highest affinity for Fe3+ with a Kd of 10-49 M (Goetz, Holmes 
et al. 2002). NGAL only binds catecholate-type siderophores. The binding of iron-loaded 
siderophore by NGAL suggests that NGAL contributes to the innate immune system by 
contributing to the antibacterial process (Flo, Smith et al. 2004). Following the finding of 
siderophore binding of NGAL, a couple of papers were published to support this finding and 
verified the stoichiometry of NGAL: siderophore: Fe was 1:1:1 by binding studies and X-ray 
crystallography. But some authors argued that iron delivery rather than iron chelation was the 
major mechanism of action of NGAL, suggesting that maybe the NGAL: siderophore: iron 
represents an alternative means of iron transport beyond the classical transferrin-mediated 
delivery (Yang, Mori et al. 2003; Mishra, Mori et al. 2004; Gwira, Wei et al. 2005; Mishra, 
Dent et al. 2005; Mori, Lee et al. 2005; Schmidt-Ott, Mori et al. 2006).  
 
The evidence for iron delivery mainly comes from renal rescue experiments  
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demonstrated mainly by two groups (Yang, Mori et al. 2003; Mishra, Mori et al. 2004; Gwira, 
Wei et al. 2005; Mori, Lee et al. 2005). The NGAL: siderophore: Fe complex is proposed to 
rescue kidney from ischemia-reperfusion (IR) renal injury by converting renal progenitors 
into epithelial tubules and inducing the transition of mesenchyma to epithelium to regulate 
epithelial development. The mechanism of this protection requires the delivery of 
siderophore: Fe to the proximal tubule and iron is the essential element (Yang, Mori et al. 
2003; Mishra, Mori et al. 2004; Gwira, Wei et al. 2005; Mori, Lee et al. 2005).  
 
By studying 71 children undergoing cardiopulmonary bypass, Dr. Jaya Mishra  
reported that NGAL could be used as a biomarker for acute renal injury after cardiac surgery 
(Mishra, Dent et al. 2005). As well as a biomarker for acute kidney injury (AKI), NGAL 
could be also used as biomarker of chronic kidney disease (CKD) by measuring either urine 
or serum NGAL concentration (Schmidt-Ott, Mori et al. 2006). NGAL could also be induced 
by bacterial colonization of the nasal mucosa in the upper respiratory tract (Nelson, Barasch 
et al. 2005). Other studies of related genes uncovered that human lipocalin 1 can also bind 
siderophores (Fluckinger, Haas et al. 2004). Hence this subset of lipocalins was suggested to 
be renamed as siderocalins (Goetz, Holmes et al. 2002; Fluckinger, Haas et al. 2004).  
 
The above findings also raise a very interesting question: Is there a mammalian  
homolog of the bacterial siderophore? Although the above described activities of NGAL 
depend on a siderophore, the observation that NGAL protects against renal ischemia 
reperfusion injury suggests that in the absence of bacteria, there should be an endogenous 
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siderophore-like ligand of NGAL. Finding this endogenous ligand now is an important goal 
in many labs.  
 
Although some of the phenomena observed for NGAL are related to siderophore and  
iron binding, there are many interesting findings unrelated to this binding property: The 
NGAL/MMP9 heterodimer was reported to be able to promote breast cancer growth (Yan, 
Borregaard et al. 2001; Fernandez, Yan et al. 2005). NGAL-overexpressing tumor cells 
exhibited increased growth rates accompanied by increased levels of MMP9, increased 
angiogenesis, and increased proliferative potential (Yan, Borregaard et al. 2001). In addition, 
NGAL/MMP9 complex was detected in around 90% of the urine samples from breast cancer 
patients but not from matched controls (Fernandez, Yan et al. 2005). The former suggests 
that NGAL may play an important role in breast cancer in vivo by protecting MMP9 from 
degradation and preserving its enzymatic activity, which facilitates angiogenesis and tumor 
growth. The latter suggests that NGAL/MMP9 could be a potential biomarker for predicting 
breast cancer status by detecting urinary NGAL-MMP9 complex concentrations (Yan, 
Borregaard et al. 2001; Fernandez, Yan et al. 2005).  
 
NGAL is one of the genes for which the expression level is upregulated most in  
human colorectal cancer cell lines and adenocarcinomas using real-time reverse transcription 
PCR analysis (Reichling, Goss et al. 2005). It is also unregulated in inflammatory bowel 
diseases (Crohn's disease (CD) and ulcerative colitis (UC)) using DermArray(R) and 
PharmArray(R) DNA microarrays (Dooley, Curto et al. 2004). 
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NGAL is also reported to be a potential cancer suppressor. It not only suppresses the  
colon cancer cells invasion but also inhibits liver metastasis in an animal experiment without 
significant impacts on normal cell proliferation, which indicates NGAL might be a metastasis 
suppressor candidate in colon cancer cells (Lee, Lee et al. 2006). Some results suggest that 
NGAL promotes cancer (Fernandez, Yan et al. 2005); other results suggest that NGAL 
inhibits cancer (Lee, Lee et al. 2006). This debate is yet on going. 
 
Uterocalin: The mouse Lcn2 (Uterocalin; Utc) was first called SIP24 because its  
molecular weight is about 24 kDa and it is secreted by quiescent Balb/c 3T3 fibroblast cells 
stimulated by growth factors and prostaglandin F2α (Nilsen-Hamilton, Hamilton et al. 1982). 
It could also be superinduced by basic fibroblast growth factor, a combination of growth 
factors and cycloheximide (Hamilton, Nilsen-Hamilton et al. 1985; Davis, Tabatabai et al. 
1991). Later the mRNA of Utc was cloned from an SV40-transformed quiescent mouse 
primary kidney cell culture and called 24p3. The Utc protein was also produced by 
lipopolysaccharide stimulated cultured mouse macrophages (Hraba-Renevey, Turler et al. 
1989; Nagai, Akashi et al. 2002). The combination of IL-6 and TNF-α or IL-6, TNF-α and 
dexamethasone could act synergistically to increase Utc production on BNL (Balb/c normal 
liver) cells (Liu and Nilsen-Hamilton 1995; Liu, Nilsen-Hamilton et al. 2003). The latter 
observation is very interesting because both pro-inflammatory and anti-inflammatory factors 
could work together to induce Utc expression. This implies that a negative feedback 
regulation might be the possible mechanism to terminate inflammation (Liu, Nilsen-
Hamilton et al. 2003).  
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This mouse protein was named uterocalin because its basal expression level is highest  
in the uterus and its expression level in the uterus around parturition is higher than the 
expression level in the liver during the APR both at mRNA and protein levels (Liu, Ryon et 
al. 1997). It is also a type I (positive) acute phase protein for which expression of mRNA and 
protein is increased dramatically in the mouse serum and liver during the acute phase 
response by intramuscular turpentine injection (Liu and Nilsen-Hamilton 1995). Utc is also 
involved in tissue involution and contributes to 0.2–0.5% of the total extractable protein of 
the involuted breast tissue. Based on reports by others that Utc induces apoptosis in a number 
of hematopoietic cell types, it was hypothesized that Utc may promote the invading 
neutrophil death and thus delay neutrophil entry into the tissue in order to give cells time to 
survive involution (Ryon, Bendickson et al. 2002; Nilsen-Hamilton, Liu et al. 2003)   
 
Like for NGAL, there are also many functions proposed for Utc. The most disputed  
opinion is that Utc induces apoptosis in leucocytes under cytokine (IL-3) depletive condition 
(Devireddy, Teodoro et al. 2001). By using an IL-3 dependent murine FL5.12 pro-B cell line, 
Devireddy et al. demonstrated that Utc was the gene that underwent maximal transcriptional 
induction after IL-3 withdrawal (Devireddy, Teodoro et al. 2001). The conditioned medium 
from IL-3 deprived FL5.12 cells contained Utc, which can induce apoptosis in naïve FL5.12 
cells even when IL-3 was present. They also demonstrated that Utc could induce apoptosis in 
other cytokine-dependent or cytokine-independent leukocytes, for example, mouse 32D, 
mouse HT-2, mouse Ba/F3 and human MT-4 but not non-leukocytic cell lines, like human 
HeLa, monkey COS-7 and mouse NIH 3T3. Some primary cells were also shown to undergo 
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apoptosis in response to Utc, including murine primary bone marrow cells, human primary 
neutrophils and human peripheral blood lymphocytes.  
 
The existence of a putative Utc cell surface receptor was suggested by the authors on  
the basis of the Utc induced apoptotic signaling through an autocrine pathway (Devireddy, 
Teodoro et al. 2001). In 2002, the same group published another paper, stating that ATFx, a 
specific mouse ATF gene which belongs to mammalian basic-region leucine zipper (bZIP) 
ATF/CREB family of transcription factors, was the most down-regulated gene in a variety of 
cells undergoing apoptosis following growth factor deprivation (Persengiev, Devireddy et al. 
2002). Their results indicated that ATFx was an anti-apoptotic factor. They also tried to 
connect the two papers’ idea together: IL-3 deprivation induces the expression and secretion 
of Utc. The secreted Utc then binds to its cell surface receptor and downstream signaling 
leads to the repression of ATFx and induces cell apoptosis (Persengiev, Devireddy et al. 
2002). Despite these publications, the Utc and apoptosis is still one of the most controversial 
topics in Lcn2 research field. One thing is that other laboratories cannot repeat these results 
(Klausen, Niemann et al. 2005; Berger, Togawa et al. 2006). It might due to the specific type 
of the cell line used by the Devireddy group (pro-B FL5.12). So their results may represent 
the response of a particular cell type rather than a general response.  
 
In 2005, a paper was published to support the conclusion that Lcn2 induces apoptosis.  
But this time, it was not in leucocytes, but in red blood cells (Miharada, Hiroyama et al. 
2005). By using in vitro and in vivo experiments, the results of this paper showed that Utc 
suppressed red blood cell (RBC) production in an autocrine fashion due to the interaction of 
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Utc with a putative receptor that was detected using the fluorescence activated cell sorter 
(FACS) (Miharada, Hiroyama et al. 2005). The authors proposed that Utc induces apoptosis 
and/or inhibits differentiation of hematopoietic progenitors to avoid the survival of excess 
cells. Once hematopoiesis is needed, the transcription of Utc is reduced to allow more cells to 
survive, proliferate, differentiate and quickly satisfy the requirements (Miharada, Hiroyama 
et al. 2005). This is the only paper from a different lab to support the idea that Utc induces 
apoptosis.  
 
Utc was reported to be able to bind fatty acid, retinoids, cholesteryl esters, which was  
detected by circular dichroism spectroscopy (Chu, Lin et al. 1998). But the association 
constant was at the uM level, which indicated they were probably not the endogenous ligands. 
Utc expression was also observed under normal conditions and was found to be highly 
expressed under chronic hyperglycemia in adipose tissue which suggested that it might have 
some relationship with fatty acid metabolism (Lin, Rajala et al. 2001; Drevon 2005).  
 
Soon after NGAL was shown to bind siderophore and iron, this was confirmed with  
Utc, which was demonstrated to deliver ferric ion to mouse spermatozoa (Elangovan, Lee et 
al. 2004). Previously Utc was found present in mouse uterine luminal fluid and later reported 
to be produced and secreted from mouse epididymal caput (Chu, Huang et al. 1996; Chu, Lee 
et al. 2000). The Utc gene is constantly expressed in spermatozoa of mice throughout their 
development and the protein is associated with the anterior acrosomal membrane of 
epididymal spermatozoa. Based on all these observations, it was suggested that Utc may play 
an important role both in spermatozoal maturation and fertilization (Chu, Lee et al. 2000). In 
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a recent report, Utc was demonstrated to bind spermatozoa, be further internalized and 
deliver ferric ion to the spermatozoa, which suggested that Utc might be a spermatozoa ferric 
ion transporter. This supports the opinion that the delivery of iron is the main function of 
Lcn2 not iron chelation (Yang, Mori et al. 2003).   
 
Utc was reported to be a potent stimulant of gastrointestinal mucosal integrity, repair  
and regeneration (Playford, Belo et al. 2006). Utc could also convert 4T1-Ras-transformed 
mesenchymal tumor cells to an epithelial phenotype, increase E-cadherin expression, and 
suppress cell invasiveness in vitro and tumor growth and lung metastases in vivo. These data 
implied that Utc might be an epithelial inducer and tumor metastasis suppressor (Hanai, 
Mammoto et al. 2005).  
 
In the September 2006 Lipocalin conference held in Iowa State University, Ames, IA,  
Dr. Felix Aligner presented evidence that Utc was elevated both at mRNA and protein levels 
in the transplanted murine heart after ischemia and reperfusion, and this was due to the 
neutrophil infiltration. He proposed that Utc may be required for the initiation of 
inflammation in vivo. Their experiments also demonstrated that Utc did not induce apoptosis 
in cardiomyocytes (Felix Aligner et al., Department of General Transplant Surgery and 
Daniel-Swarovski-Research Laboratory, Innsbruck Medical University, Austria).  
 
In an in vivo experiment using Lcn2-deficient (Lcn2-/-) mice, Dr. Thorsten Berger  
demonstrated that Lcn2-deficient mice exhibited increased sensitivity to E. coli infection but 
not to ischemia-reperfusion injury and leukocyte apoptosis induction (Berger, Togawa et al. 
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2006). But for the renal rescue, authors also suggested that the observed discrepancy might 
be due to the kinetics of the expression of endogenous Lcn2 after ischemia-reperfusion injury. 
A shorter ischemia time and a longer reperfusion might reduce the observed differences 
(Berger, Togawa et al. 2006).  Lcn2-/- mice can survive embryonic development and behave 
normally during adulthood except that Lcn2-/- females show significantly decreased fertility 
compared with WT, which supports the previous report that Lcn2 may facilitate sperm 
maturation and fertility (Chu, Lee et al. 2000). This paper suggests that there is an Lcn2 
redundant gene because the knockouts survived the embryonic stage and look fine as adults.  
 
There are two receptors identified for Lcn2. The first one is called 24p3 R, which was  
identified by expression cloning using a cDNA library prepared from murine FL5.12 cells 
(Devireddy, Teodoro et al. 2001). It was reported that ectopic expression of 24p3R endowed 
cells with the ability to undergo either iron uptake or apoptosis depending on the iron ligand 
status. If Utc is iron loaded, the release of iron will increase the intracellular iron 
concentration without inducing apoptosis. If Utc lacks iron, the intracellular iron 
concentration will be decreased by the binding of iron to the siderophore, and then iron is 
transferred to the extracellular medium by Utc. The decrease of iron concentration induces 
expression of the pro-apoptotic protein Bim which results in apoptosis (Devireddy, Gazin et 
al. 2005). This paper elegantly connected the effect on apoptosis with decreased iron 
concentration by binding to siderophore. But it showed no evidence of direct interaction of 
Utc and 24p3R, which leaves a question: Is the 24p3R the really specific receptor for Utc or 
it is just one of the Utc-mediated cellular signaling pathway players? The answer to this 
question is still pending.  
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The second reported NGAL receptor is megalin, also know as gp330, one of the  
largest vertebrate membrane receptors. Megalin is a muti-ligand endocytic receptor and 
belongs to low density lipoprotein receptor family. It is also known to bind several other 
lipocalins, including retinol binding protein, α1-microglobulin, mouse major urinary protein 
and odorant binding protein. By using surface plasmon resonance analysis, megalin was 
demonstrated to bind NGAL with high affinity. In a rat yolk sac cell line from Brown 
Norway rats which expresses high levels of megalin, the endocytosis of NGAL by binding 
megalin was visualized using fluorescence technique. This endocytosis was completely 
blocked by an antibody against megalin (Flower 2000; Hvidberg, Jacobsen et al. 2005). But 
the authors also stated that it was possible that specific receptors other than megalin may be 
involved in cellular uptake of NGAL (Hvidberg, Jacobsen et al. 2005).  
 
EX-FABP: The chicken Lcn2 was called Ch21 at the beginning because its molecular  
weight is around 21 kDa. In 1996, Ch21 was reported to bind long-chain unsaturated fatty 
acids at 0.2 nM dissociation constant. Oleic, linoleic, and arachidonic acid, were 
preferentially bound. From then on, this chicken protein was renamed EX-FABP 
(Extracellular Fatty Acid Binding Protein) (Cancedda, Malpeli et al. 1996). EX-FABP is 
highly produced by peripheric granulocytes, which may due to the requirement of the fatty 
acid substrates for the synthesis of prostanoids and other metabolites by inflammatory cells 
(Cancedda, Malpeli et al. 1996). EX-FABP is expressed in chondrocytes, myoblasts, and 
cardiomyocytes in chicken. The expression of EX-FABP is upregulated by C/EBP at the 
promoter level (Savoldi, Fenaroli et al. 1997). Recently, EX-FABP was reported to act as a 
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survival protein by playing a role as scavenger for fatty acids. This was demonstrated by 
blocking the function of this protein by injecting EX-FABP antibody directly in chicken 
embryo at early stage of development led to the accumulation of fatty acids, which resulted 
in cell apoptosis and final embryo death. They observed 70% of the embryos died in 24 h and 
the major target tissue was the heart (Gentili, Tutolo et al. 2005).  
 
NRL: The rat Lcn2 protein is called Neu Related Lipocalin (NRL). NRL is over- 
expressed in rat mammary cancer which is induced by the activation of oncogene neu (HER-
2/cerbB2) (Stoesz and Gould 1995). It was reported to be involved in cartilage and muscle 
differentiation and its expression can be induced by inflammatory agents. Based on the 
observation that NRL is expressed in hypertrophic chondrocytes and myotubes during 
normal cartilage and muscle development respectively, it is hypothesized that NRL plays 
roles in differentiation and inflammation (Zerega, Cermelli et al. 2000).  
 
INFLAMMATION 
Inflammation is the first response of the immune system to bacterial or viral infection.  
During this process, leucocytes and the chemicals released by them play roles in protecting 
the host from foreigh substances (Gwyer, Snelgrove et al. 2006; Tchorzewski 2006). 
Inflammation has five well-established characteristics: redness, heat, swelling, pain and 
dysfunction of the involved organs. There are also some “flu-like” symptoms associated with 
inflammation, such as fever, chill, headache, diarrhea, fatigue or loss of appetites. The two 
main components of inflammation as mentioned above are the inflammatory cells and 
exudates composed of the chemicals released from cells and plasma facotors. White blood 
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cells are the soldiers that fight the battle, mainly including neutrophils and macrophages. 
Chemicals mediators include histamine, lysozyme, prostaglandins and cytokines. Plasma 
factors contain complements, kinins, coagulation factors and fibrin that work together with 
the chemical mediators to fully activate the immune system (Tchorzewski 2006). Generally 
there are four possible outcomes of inflammation: Resolution, scarring, abscess formation 
and chronic inflammation. Resolution means the complete recovery of infectious tissue to 
normal status without any loss of function. The shift of prostaglandin synthesis from E2 to 
D2 was reported to promote this phase (Schuligoi, Grill et al. 2005). Scarring is mainly 
related to excess fibroblast and myo-fibroblast activities. Abscess formation usually happens 
by infection with resistant pyogenic bacteria. Chronic inflammation is the extension of acute 
inflammation and may last up to days, months or even years (Taub and Oppenheim 1994; 
Bertolino, Klimpel et al. 2000).  
 
Neutrophils: Neutrophils, the most abundant leucocytes (~70%), are characteristic of  
early acute inflammation. They are the first leucocytes show up at the site of infection. They 
are easily identified under microscope by their multi-lobed nuclei and cytoplasmic granules. 
The average half-life of an inactivated neutrophil is around 4-10 h. Once activated by 
cytokines or chemokines, neutrophils stop strolling in the blood vessel, cross the endothelium 
and transmigrate to the infectious area with the help of adhesion molecules (selections, 
integrins). There they usually can live for a couple of days. The primary function of 
neutrophils is phagocytosis. In additon to the phagocytotic function, neutrophils can also 
release chemical mediators, such as myeloperoxidase, proteases and gelatinase, which are the 
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enzymes actively involved in inflammation (Faurschou and Borregaard 2003; Wiedow and 
Meyer-Hoffert 2005; Komatsu, Koyama et al. 2006; Pham 2006).  
 
Macrophages: The macrophage is another phagocytotic cell type involved in  
inflammation. They differentiate from monocytes, which are derived from the bone marrow. 
Once monocytes are directed to the target tissues by signals, they mature into macrophages. 
Although macrophages exist in the early stage of inflammation together with neutrophils, 
they are the dominant cell type in the later phase of inflammation and mainly responsible for 
the maintenance of inflammation (Titov 2003; Singh, Pearce et al. 2004). In the latter 
situation, macrophages can live from months to years. Macrophages are the strongest 
phagocytes, once activated by cytokines, histamines or pathogens. They ingest foreign 
substances by phagocytosis to form phagosome. Later, lysozymes infuse with the 
phagosomes and the microbial invaders are broken down and debris is released by the cell 
(Knudsen, Benestad et al. 2004; Medvets'kyi Ie, Zubkov et al. 2004; Fujiwara and Kobayashi 
2005).  
 
Mast cells: Although mast cells are well known for their roles in IgE-mediated  
allergy (Nigo, Yamashita et al. 2006), they also play a protective role in inflammatory 
process such as producing inflammatory mediators to mount the acute phase response and 
ingesting bacteria to present antigens to immune cells (Ramirez-Romero, Brogden et al. 
2001). Two types of mast cells have been identified, one is from the connective tissue and 
one is from the mucosa. Mast cells are present prominently at the boundary site between the 
outside and inside of the body, such as skin, nose, mouth, mucosa of the lung and digestive 
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tract. Mast cells can easily be recognized under microscope because of the large number of 
granules, which are rich in histamine, protaglandin and heparin. Histamine is released by 
mast cells upon activation. It is not only a strong vasoactive compound, which can activate 
the endothelium and increase vessel permeability, but is also a potent inflammatory mediator 
to attract other inflammatory cells to the site of release (Hartung and Toyka 1989; Kiyono, 
Kweon et al. 2001; Prussin and Metcalfe 2003; Fukuishi, Yoshioka et al. 2005; Prussin and 
Metcalfe 2006). Mast cells usually undergo degranulation during an acute inflammatory 
response, which can be induced by substance P (SP), a sensory neuropeptide from 
unmyelinated sensory nerves (C-fibers) (Ramirez-Romero, Gallup et al. 2000; Ramirez-
Romero, Brogden et al. 2001). Giemsa, low pH toluidine blue and tryptase 
immunohistochemistry are three routine methods used to identify mast cells in the lab 
(Ramirez-Romero, Brogden et al. 2000).   
 
Dendritic cells: Dendritic cells (DCs) are the least studied inflammatory cells  
because of their small quantities in tissues and the difficulty of isolating them. In addition to 
being well-known for their antigen presenting capability, dendritic cells are also able to 
produce pro-inflammatory mediators, such as prostanoids from arachidonic acid (AA), to 
modulate the inflammatory process (Gualde and Harizi 2004). Dendritic cells are also well 
recognized to play a critical role in LPS-elicited inflammatory reactions. When DCs are 
activated by LPS through TLR4, they mature and gain increased ability to activate T cells 
(Akira, Takeda et al. 2001). A recent study showed that dexamethasone and LPS could act 
synergistically on dendritic cell maturation and migration, during which the expression of 
Utc was induced. The authors proposed that Utc plays a role in DC-mediated T cell depletion 
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(Vizzardelli, Pavelka et al. 2006). Immature dendritic cells travel through the blood to enter 
the peripheral tissues. Once activated, they mature and migrate to the lymphoid tissues to 
activate T cells and B cells. Both lymphoid progenitors and myeloid progenitors give rise to 
some portions of dendritic cells, but the whole developmental pathway hasn’t been clarified 
yet. DCs are also easy to identify under the microscope because their branched projections 
give them a unique star-like shape (Banchereau 2002; McKenna, Beignon et al. 2005).  
 
Inflammation is a double-edged sword. If it is well regulated, it is definitely a benefit  
to the host by warding off pathogens. But exaggerated inflammation can contribute to disease 
severity, such as sepsis, asthma, and appendicitis and tumor formation. The most popular two 
types of anti-inflammatory drugs are steroidal anti-inflammatory drugs, such as 
glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs). These drugs interfere 
with inflammatory process partly by acting on cyclooxygenase (COX) enzymes to impair 
prostaglandin synthesis (Braddock and Murray 2006). NSAIDs are well known to contribute 
to stomach ulcers, so people are actively looking for some natural substitutes (Lanas Arbeloa 
and Serrano Aullo 1998). Recently, capsaicin, a natural ingredient from chili peppers, was 
demonstrated to be a very promising candidate for controlling pain and inflammation 
(Larauche, Anton et al. 2004; Manjunatha and Srinivasan 2006). 
    
ACUTE PHASE RESPONSE AND ACUTE PHASE PROTEINS 
The acute phase response (APR) is a complicated process triggered by bacterial or  
viral infection, stress, injury, trauma, inflammation or malignancy. Immediately following 
the initiation of the APR, pro-inflammatory cytokines are released and the vascular system 
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and inflammatory cells are activated. The APR is characterized by leukocytosis, fever, 
alterations in the metabolism of many organs as well as changes in the concentrations of 
several plasma proteins, called the acute phase proteins (APPs). The liver is the major organ 
that produces the APPs and the changes in APP levels can last 48 h or even longer (Liu, 
Ryon et al. 1997). As well as by the liver, APPs are produced by other epithelial cells in 
response to stress (Liu, Nilsen-Hamilton et al. 2003). It is important to keep in mind that 
physiologically, APPs can be produced during pregnancy and parturition in the adult animals 
(Liu and Nilsen-Hamilton 1995; Koets, de Schwartz et al. 1998; Eckersall, Young et al. 2001; 
Gruys, Toussaint et al. 2005). The purpose of this response is believed to prevent ongoing 
tissue damage, segregate and to destroy the infective organism’s ability to restore 
homeostasis (Gauldie, Lamontagne et al. 1985; Renckens, Roelofs et al. 2006).  
 
There are two types of APPs; one is the positive acute phase protein, also called type  
I APPs, such as C-reactive protein, serum amyloid A, fibrinogen, α1-acid glycoprotein and 
Uterocalin (Liu, Ryon et al. 1997; Heinrich, Behrmann et al. 1998; Morlese, Forrester et al. 
1998; Jensen 2000; Herran, Sierra-Biddle et al. 2005). Their plasma concentrations are 
increased during the APR. The other group, type II APPs, is negative acute phase proteins, 
such as transthyretin, retinol binding protein, cortisol binding globulin and transferrin (Gruys, 
Toussaint et al. 2006). Their plasma concentrations are decreased during the APR. Based on 
the plasma concentration increase, positive APPs could be generally classified into three 
categories: 1) an increase of about 50%, representative: complement factor-3; 2) an increase 
of 2-3 fold, representative: fibrinogen; 3) rapid increase of up to 5-1000 fold, representative: 
C-reactive protein, serum amyloid A and Utc (Cambau 1988; Schultz and Arnold 1990; Liu, 
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Ryon et al. 1997; Lannergard, Larsson et al. 2003; Gruys, Toussaint et al. 2005; Lannergard, 
Friman et al. 2005).  
 
The functions of most APPs have not been well established. Usually the decrease of  
negative APPs indicate a temporarily decreased availability of free factors bound to these 
proteins (Ingenbleek and Young 1994). Positive APPs are generally thought to be anti-
inflammatory via activation of complement, neutralization of enzymes, scavenging of free 
radicals or modulation of the host’s immune system (Gruys, Toussaint et al. 2005).  An acute 
phase index measured by the consideration of combined negative and positive APPs is used 
as prognostic inflammatory and nutritional parameter for human patients (Gruys, Toussaint et 
al. 2005). The major APP stimulators are the inflammation-associated cytokines, which are 
produced during the inflammatory process by activated immune cells, such as neutrophils 
and macrophages (Wigmore, Fearon et al. 1997).  
 
CYTOKINES 
Cytokines are a group of small water soluble proteins and glycoproteins, most with 
molecular masses of 8-30 kDa. They are involved in almost every facet of the innate and 
adaptive immune responses. Cytokines are linked with a variety of immunological, 
inflammatory and infectious diseases and play important roles in developmental processes 
during embryogenesis (Borish and Steinke 2003). Cytokines are produced by a wide variety 
of cell types after inflammatory stimuli. Most cytokines are produced by monocytes and 
other antigen-presenting cells (APCs) (Borish and Steinke 2003; Steinke and Borish 2006). 
Each cytokine has its own specific cell surface receptor. The binding of cytokine with its 
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receptor triggers subsequent intracellular signalling cascades, which finally turn on the target 
gene expression including genes that encode other cytokines. Generally cytokines are found 
to be redundant, which means many cytokines can share similar functions. The functions of 
cytokines are quite complicated and very difficult to generalize. But they can act either in an 
autocrine manner (the cytokine acts on the cell that secretes it), paracrine manner (the action 
is restricted to the neighbouring regions of the cytokine secreting cells) or endocrine manner 
(the cytokine diffuses to distant regions through blood stream to affect other cells or tissues). 
Cytokines are usually present at very low concentrations at µg/ml or pg/ml level. Different 
combinations of cytokines can have different functions which might be synergistic, inhibitory 
or modulatory (Brown, Grosso et al. 1989; Dudrick and Souba 1994).  
 
Cytokines can be classified into three categories based on their distinguishable 
biological effects: 1) cytokines that primarily act as positive growth factors or inhibitors for a 
variety of cells. Representatives are IL-2, IL-3, IL-4, IL-7, IL-10, IL-11, and IL-12. 2) 
cytokines with pro-inflammatory properties. Representatives are TNF-α/β, IL-1α/β, IL-6, 
IFN-α/γ, and IL-8. 3) cytokines with anti-inflammatory properties. Representatives are IL-4, 
IL-1 receptor antagonists (IL-1rα), TGF-β, soluble TNF-α receptor, IL-13 and members of 
IL-10 family (van Miert 1995). An inflammatory process usually leads to the activation of 
the cytokine network with which immune cells have intense communications; and the release 
of cytokine is tightly regulated. In the early phase of this process, pro-inflammatory 
cytokines are released. The activity of the pro-inflammatory cytokines is counteracted by the 
production of anti-inflammatory cytokines and soluble inhibitors of pro-inflammatory 
cytokines (van der Poll and van Deventer 1999; Golab 2000).  
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In cancer, there is evidence that inflammation plays an essential role at each stage 
including initiation, proliferation and metastasis. Inflammatory cells are capable of directly 
or indirectly inhibiting or promoting tumor growth (Fidler 2000). Tumor development has 
been well demonstrated to correlate with the presence of inflammatory reactants. Cytokines 
are therefore ascribed to be inflammation-associated cancer mediators. It is implied that the 
interactions exist between the cytokines produced in response to inflammation and tumor 
growth and that the inflammatory cytokines may facilitate tumor formation (Fidler 2000; 
Macarthur, Hold et al. 2004). Among cytokines, CSF-1 (Colony Stimulating Factor 1), TGF-
α (Transforming Growth Factor α) and TNF-α (Tumor Necrosis Factor α) are heavily 
involved in this tumor-related process, mainly by mediating monocyte recruitment to tumors 
that later mature to be tumor-associated macrophages (TAM). TAM and other leukocytes at 
the tumor site secrete cytokine mediators, which are implicated to play a key role in immune 
suppression, thereby accelerating tumor formation (Ben-Baruch 2006). A key point 
concerning the influence of cytokines on inflammation or cancer is the balance between the 
pro-inflammatory and anti-inflammatory cytokines. Once the balance is broken, malignancy 
will spread (Parmiani 1998; van Dissel, van Langevelde et al. 1998). 
Tumor necrosis factor: The tumor necrosis factor (TNF) family is composed of two 
homologous proteins; one is TNF-α, which is primarily derived from monocytes. The other is 
TNF-β, which is mainly derived from lymphocytes (Beutler and Cerami 1989). The active 
form of both TNFs is a homotrimer when they bind to their receptors and trigger downstream 
signaling cascades.  In addition to monocytes, TNF-α is also produced by neutrophils, mast 
cells or activated lymphocytes (plasma B cells and activated T cells). Endothelial cells also 
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produce some TNF-α (Borish and Steinke 2003). TNF-α is a 185 amino acid glycoprotein 
that is cleaved from a 212 amino acid propeptide on the surface of  macrophages. Shorter or 
longer isoforms are also secreted by other cells (Perez, Albert et al. 1990).  
Unlike TNF-α, TNF-β (LT-α) has no cell membrane attachment domain but it can 
form membrane-associated heterotrimers with LT-β, another membrane-anchored TNF 
family member. TNF-β is synthesized and processed as a typical secretory protein (Borish 
and Steinke 2003). There are two distinct cell surface receptors for TNFs, TNFR I (p55) and 
TNFR II (p75). TNFs bind to the TNFRs with similar affinities but not exactly with the same 
effects (Borset, Medvedev et al. 1996). Both TNFs can interact with endothelial cells to 
induce adhesion molecule expression, such as intracellular adhesion molecule (ICAM), 
vascular cell adhesion molecule (VCAM) and selection. These adhesion molecules promote 
the attachment of granulocytes to the endothelium and facilitate their migration to target 
tissues. The TNFs are potent attractors for neutrophils during inflammation. Although TNFs 
were firstly isolated as soluble factors released by host cells that caused necrosis of a 
transplanted tumor, they also contribute to chronic inflammation and tumor formation 
(Carswell, Old et al. 1975; Beutler and Cerami 1989; Ben-Baruch 2006). Anti-TNF 
monoclonal antibodies are made as drugs to treat the autoimmune disorders caused by TNFs 
and some TNF inhibitors are found in nature, such as curcumin (an ingredient in turmeric) 
and catechins (a component of green tea) (Lantz, Chen et al. 2005; Gulcubuk, Altunatmaz et 
al. 2006; Okunieff, Xu et al. 2006; Siddiqui, Cui et al. 2006). 
Interleukin 1 (IL-1): The interleukin-1 family was recently reported to be composed  
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of four proteins: IL-1α, IL-1β, IL-1ra (IL-1 receptor antagonist) and a new member, IL-18 
(Dinarello and Wolff 1993; Dinarello 1994; Huising, Stet et al. 2004). In addition, a couple 
of structural homologies were also found and await the proper classification and 
nomenclature. Because of the large number of family members, people refer to them the IL-1 
superfamily (Dunn, Sims et al. 2001; Sims, Nicklin et al. 2001). IL-1 was initially discovered 
as a factor that could induce fever, regulate lymphocytes and increase bone marrow cell 
numbers. IL-1α and IL-1β are pro-inflammatory cytokines involved in immune defence 
against infection. IL-1ra competes with IL-1α and IL-1β for receptor binding to block their 
functions.  
 
There are two types of IL-1 receptors (IL-1Rs). Type I receptors are the major IL-1  
receptors that transmit IL-1 triggered intracellular signals (Sims, Gayle et al. 1993). Type II 
receptors are inactive and do not participate in IL-1 signaling due to their minimal 
intracellular domains. The type I receptor is the major target of IL-1ra. IL-1ra is secreted 
during inflammation and is thought to modulate the potentially deleterious effects of IL-1 in 
inflammation (Lewis, Varghese et al. 2006). IL-1α, IL-1β and IL-18 are originally 
synthesized as precursors in an inactive state. IL-1 converting enzyme (ICE), also called 
caspase 1, cleaves the precursors and converts them into their active secretory forms (Ellis, 
Oppong et al. 2006). IL-1 is secreted mainly by macrophages, monocytes and dendritic cells. 
It plays an important role in the inflammatory response of the body against infection. It can 
also increase the expression of adhesion molecules on endothelial cells to enhance the 
transmigration of leukocytes to the site of infection. In addition, IL-1 can activate T cells; 
promote B cell proliferation and immunoglobulin synthesis.  
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Interleukin 6 (IL-6): Interleukin 6 is a pro-inflammatory cytokine primarily secreted  
by T cells and macrophages during inflammation. IL-6 is also called myokine because it can 
be produced by muscle and is involved in the osteoclastogenesis (Febbraio and Pedersen 
2005; Wong, Quinn et al. 2006). IL-6 is one of the most important cytokines to induce fever 
and acute phase response. In addition to being a pro-inflammatory cytokine, IL-6 also 
participates in several anti-inflammatory activities. It can terminate the positive inflammatory 
cascade by inhibiting either TNF synthesis or IL-1 synthesis, sometimes by stimulating 
synthesis of IL-1ra (Xing, Gauldie et al. 1998; Wong, Quinn et al. 2006). IL-6 is also one of 
the important cytokines involved in chronic inflammation and tumor progression (Gabay 
2006; Rose-John, Scheller et al. 2006; Scheller, Ohnesorge et al. 2006). IL-6 initiates signal 
transduction by binding to its cell surface receptor complex which consists of CD126, a 
ligand binding chain of the IL-6 receptor (IL-6Rα) and gp130, the signal transducing effector. 
gp130 is a universal signal transducer also used in other signaling pathways, such as 
leukemia inhibitory factor induced pathway. It is ubiquitously expressed in most cells. 
Interaction of IL-6 with its receptor triggers the formation of gp130 and IL-6R complex, 
which brings together the intracellular regions of gp130 to initiate a signal transduction 
cascade through downstream adaptors, like JAKs (Janus kinases) and STATs (Signal 
Transducers and Activators of Transcription) or SHP-2 (protein phosphatase 2) and GRB2 
(Growth Factor Receptor-Bound Protein 2) (Belka, Ahlers et al. 1995; Henttinen, Levy et al. 
1995; Watanabe, Saito et al. 2004; Zhang, Badgwell et al. 2006). In addition to IL-6, other 
cytokines also use gp130 as part of their signaling cascade, such as IL-11 and IL-27. Because 
IL-6 is probably the best studied cytokine that uses gp130 in its signalling, other cytokines 
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are usually referred to as IL-6-like or gp130-utilizing cytokines. In addition to the membrane-
bound receptor, a soluble form of the IL-6R (sIL-6R) has been purified from human serum 
and urine. It is reported that the enhanced effect of IL-6 on platelet function might be due to 
the binding of sIL-6R/IL-6 complex to the platelet membrane through gp130 (Marta, Goette 
et al. 2005). The sIL-6R is also a potent promoter of AIDS-associated cells growth and a 
soluble form of gp130 is antagonistic to this activity (Murakami-Mori, Taga et al. 1996).  
 
TOLL LIKE RECEPTOR 
A Toll receptor was originally identified in Drosophila as an essential receptor for  
establishment of the dorso-ventral pattern in developing embryos (Hashimoto, Hudson et al. 
1988). Subsequently, mammalian homologues of the Toll receptor were identified and later 
they were named Toll-like receptors (TLRs). So far, the TLR family has more than 10 
members (TLR1 to TLR10). Functional analysis of mammalian TLRs revealed that the TLRs 
recognize motifs used by pathogens and not by mammalian cells. TLRs are capable of 
activating innate immune responses strongly. Therefore, TLRs are said to be a family of 
pattern recognition receptors (PRRs) (Dauphinee and Karsan 2006). TLR2 recognizes 
microbial glycolipids, lipopeptides and peptidglycan. TLR3 is essential for the recognition of 
viral-derived dsRNA. TLR4 especially recognizes gram-negative bacterial LPS, also heat 
shock protein 6, taxol and lipoteichoic acid. TLR5 is a receptor for flagellin and bacterial 
lipoproteins. TLR1 and TLR6 together with TLR2 recognize bacterial lipopeptides and 
proteoglycans separately. TLR9 is essential for CpG DNA recognition (Borish and Steinke 
2003; Takeda and Akira 2004). For the TLR signaling pathway, MyD88 was the first 
identified component and found to be a common adaptor used by all the TLRs.  
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TLR4 has been studied extensively because it is the critical receptor for recognizing  
bacterial LPS. TLR4 is identified based on the genetic evidence that C3H/HeJ mouse strain is 
LPS-insensitive because it has a single point mutation in the cytoplasmic domain of TLR4 
(Poltorak, He et al. 1998). The TLR4 signaling cascade is initiated following LPS binding to 
its receptor complex. Dimerization of TLR4 subsequently recruits MyD88 (myeloid 
differentiation factor 88) to the cytoplasmic TIR (Toll/IL-1 receptor) domains (Zhang, Tay et 
al. 2002; Akira and Takeda 2004). Recent publications indicate that TLR signaling pathways 
minimally consist of a MyD88-dependent pathway that is common to all TLRs, and a 
MyD88-independent pathway that is specific for the TLR3 and TLR4 signaling pathways 
(Takeda and Akira 2004). The main components of the MyD88-dependent pathway include 
MyD88, IRAK (IL-1 receptor-associated kinase, a serine/threonine kinase associated with the 
IL-1 receptor) and TRAF6 (tumor necrosis factor receptor (TNFR)-associated factor) 
(Takeda and Akira 2004). Finally the target genes are turned on though the activation of NF-
κB and the MAPK (mitogen-activated protein kinase) pathway that regulate the balance 
between cell viability and inflammation (Figure 3) (Takeda and Akira 2004; Dauphinee and 
Karsan 2006). 
 
LPS SIGNALING PATHWAY 
LPS (lipopolysaccharide), also called endotoxin, is a key component of the Gram- 
negative bacterial cell wall (Alexander and Rietschel 2001). The term endotoxin came from 
the discovery that portions of Gram-negative bacteria itself can cause toxicity. Although the 
terms endotoxin and LPS are often interchangeably used, they are not exactly the same thing. 
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Endotoxin refers to any toxin that is present on the bacterial cell wall. It could be LPS, it 
could be bacterial proteins and it could be any other constituents. LPS, on the other hand, 
only refers to purified lipopolysaccharide without any associated cell wall constituents 
(Beutler and Rietschel 2003). LPS is the key inducer of inflammation in human (Thorn 2001; 
Brass, Savov et al. 2003). It is composed of three structural elements: 1) O-specific chain, 2) 
a core oligosaccharide region and 3) a lipid A part. The O-specific chain is made of repeated 
polysaccharide units that promote the water solubility of LPS. It also determines the bacterial 
species because of the specific structures of the different lipopolysaccharides. The core 
region is actually an extension of the O-specific chain. It is less variable structurally than the 
O-specific chain and is located in the middle of the O-specific chain and lipid A. It can be 
divided into an outer core region and an inner core region. The inner core region is linked to 
lipid A; together they are responsible for the toxicity induced by LPS (Dauphinee and Karsan 
2006). The molecular weight of a single LPS molecule is approximately 10 kDa but it can 
form large aggregates up to 1000 kDa. It is not yet understood if the LPS monomer or the 
LPS polymer facilitates the interaction between bacteria and host in order to trigger the toxic 
reaction (Beutler and Rietschel 2003). Injection of a small amount of LPS into human 
volunteers induced fever, lower blood pressure, activation of inflammation, release of acute 
phase proteins and coagulation (Thorn 2001; Klausen, Niemann et al. 2005). LPS is present 
in the air and dust that can easily contaminate lab reagents. LPS is also freqently found in 
plasmid DNA or proteins prepared from bacteria and should be removed before the use of the 
reagents. Heating to 400oC was reported to break down the LPS structure and to eliminate its 
toxicity (Bouillard, Devleeschouwer et al. 2006; Wakelin, Sabroe et al. 2006).  
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The LPS binding protein (LBP), a 60 kDa serum glycoprotein and an acute phase  
protein is the first host protein involved in the recognition of LPS (Schumann, Leong et al. 
1990). Its role is to bring LPS to the cell surface by binding to LPS and the LPS surface 
receptor complex. Previously, LBP was believed to enhance the inflammatory response 
induced by LPS by binding the lipid A portion of LPS to form a high affinity LBP/LPS 
complex (Jack, Fan et al. 1997; Brass, Savov et al. 2004). The spontaneous diffusion of LPS 
monomers to the binding site is very slow and LBP can increase this process up to 1000-fold 
in vitro. But recently, it was reported that whether LBP facilitates or inhibits LPS-induced 
lung inflammation depends on the LPS dose. LBP promotes lung inflammation at low LPS 
doses (<10 ng) but diminishes inflammation at higher LPS doses (>10 ng) (Knapp, Florquin 
et al. 2006). LBP helps the host to respond to small amounts of LPS by transferring LPS to 
its surface receptor complex CD14/TLR4/MD2 but contributes to the neutralization of higher 
dose of LPS by transferring LPS to lipoproteins (Knapp, Florquin et al. 2006). LBP seems to 
play an important balancer role in this LPS battle. The LPS receptor complex is composed of 
three molecules: CD14, TLR4, and MD2. TLR4 is the central receptor that signals the 
presence of LPS to the cell, which results in the production of pro-inflammatory cytokines 
and chemokines. Two CD14 forms were found, one is a membrane-bound 
glycosylphosphatidylinositol (GPI)-anchored protein (mCD14) and the other is a soluble 
proteolytic fragment lacking the GPI anchor (sCD14). Some cell types express both forms 
and some only express one. Because CD14 lacks a transmembrane domain, it does not have 
the capability to initiate intracellular signaling events. CD14 strongly facilitates the 
interaction between LPS and MD2 (Wright 1995). MD2 is a secreted glycoprotein that 
associates with the extracellular domain of TLR4 and functions necessarily for LPS-induced 
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signaling events (Wright, Ramos et al. 1990; Schumann 1992; Nagai, Akashi et al. 2002; 
Knapp, Florquin et al. 2006; Kobayashi, Saitoh et al. 2006).  
 
The LPS signaling pathway leads to the activation of NF-κB (Nuclear Factor kappa  
B). NF-κB is a nuclear transcription factor that is found in all cell types and is activated by a 
variety of stimuli such as stress, inflammation, free radicals, ultraviolet irradiation, and 
bacteria or virus. The activation of NF-κB turns on the expression of genes encoding 
inflammatory cytokines, chemokines, adhesion molecules, immune receptors, acute phase 
proteins, COX-2 (cyclooxygenase-2) and iNOS (inducible nitric oxide synthase). These 
inflammatory mediators then initiate the second signaling cascades that also act on NF-κB 
and amplify signals (Baeuerle and Henkel 1994; Siebenlist, Franzoso et al. 1994).  
 
Five members were found in the mammalian NF-κB family, they are NF-κB1 (p50),  
NF-κB2 (p52), RelA (p65), RelB and c-Rel. NF-κB proteins also exist in lower organisms, 
such as the fruit fly Drosophila and sea urchins. All the NF-κB members share a Rel 
homology domain at N-terminal. The NF-κB1 and NF-κB2 proteins are originally 
synthesized as large precursors, p105 and p100, which then undergo processing to generate 
the mature NF-κB proteins, p50 and p52, respectively. This processing is mediated by the 
ubiquitin/proteasome pathway and involves selective degradation of their C-terminal regions 
(Karin and Ben-Neriah 2000; Senftleben, Cao et al. 2001).  
 
The activation of NF-κB is tightly controlled by its inhibitory protein, I-κB (Inhibitor  
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of kappa B), which is normally present in the cytosol associated with NF-κB dimers. By 
using its ankyrin repeat domains, I-κB can mask the nuclear localization signals (NLS) of 
NF-κB and sequester it in the cytosol in an inactive state, which prevents the nuclear 
localization of NF-κB and guarantees low basal transcriptional activity from NF-κB-
stimulated promoters. Upon stimulation, two serine residues of I-κB are phosphorylated (32 
and 36 in human) by the I-κB kinase (IKK). I-κB is subsequently ubiquitinated, and degraded 
by the 26S proteasome pathway. The degradation of I-κB uncovers the NLS of NF-κB, which 
allows its translocation into the nucleus, thereby facilitating DNA binding and target gene 
expression (Barnes and Karin 1997; Poynter, Irvin et al. 2003; Barnes 2006; Park and 
Christman 2006).  
 
NF-κB is widely used by eukaryotic cells as a regulator of cell proliferation and  
survival. It is not surprising that NF-κB is found to be misregulated in different types of 
tumors, in which NF-κB is found always in the active form. Active NF-κB turns on crucial 
gene expression that keeps the cell proliferating and protects it from death. Normally there 
are two reasons that keep NF-κB always active: mutations in genes encoding NF-κB or 
mutations in genes that control NF-κB activity, such as I-κB. Based upon the above reasons, 
finding ways to block NF-κB activity as an anti-cancer candidate has been one of the hottest 
research topics in academia and pharmaceutical companies for decades (Tozawa, Sakurada et 
al. 1995; Srivastava and Singh 2004; Shehata 2005). In addition to cancer, NF-κB controls 
many genes involved in inflammation and it is found to be involved in many inflammatory 
diseases. Both respiratory epithelial cells and type II alveolar epithelial cells were reported to 
be involved in LPS induced lung inflammation based on the activation of local NF-κB (Sunil, 
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Connor et al. 2002; Skerrett, Liggitt et al. 2004). Many natural products (including anti-
oxidants) with anti-cancer or anti-inflammatory activity have been shown to directly or 
indirectly inhibit NF-κB activity (Barnes and Karin 1997; Poynter, Irvin et al. 2003; Park and 
Christman 2006).  
 
CURRENT STUDIES 
Based on the knowledge that Utc is an acute phase protein involved in inflammation  
and the innate immune response, and the results from our lab that Utc expression is increased 
in the mouse lung and liver in response to LPS challenge, we proposed that Utc might play 
an anti-inflammatory role. To investigate the hypothesis, we chose to use a mouse model, in 
which Lcn2-deficient mice and wild type littermates are tested in parallel. LPS was chosen as 
the reagent to induce inflammation based on our preliminary results. The mice were treated 
with or without three different doses of LPS in PBS or PBS alone by dropping the liquid into 
their nasal cavities. CO2 was used for anesthesia and sacrifice. The mRNA levels of three 
cytokines, TNF-α, IL-1β and IL-6 were measured by multiplex RT-PCR and PAGE using 
cyclophilin as the internal control and by real-time RT-PCR using GAPDH as the internal 
control. The wild type Utc mRNA level was also measured by real-time RT-PCR. The time 
period of the treatment was 6 h. This time period was chosen because it is long enough to 
trigger inflammation. Sections of the lung and liver from treated KO and WT animals were 
stained with H & E to assess lesions and inflammatory cell infiltration.        
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MATERIALS AND METHODS 
 
MATERIALS 
His-tagged bacterial recombinant proteins, his-Utc, his-ExFABP and his-NGAL,  
were prepared using Superflow Ni-NTA column from Qiagen. XL1-Blue bacteria 
transformed with pTrcHisUtc2 plasmid and pTricHisNgal plasmid were constructed by Joel 
Ryon. XL1-Blue bacteria transformed with pcEXFABP/pTrcHis /EMW1 plasmid were 
prepared by Erin Will. Polyclonal Utc antibody was produced in rabbit by Tom Davis. Trizol 
Reagent, DNase I amplification grade, SuperScriptTM II reverse transcriptase and proteinase 
K were purchased from Invitrogen. QIAquick gel extraction kit was from Qiagen. 
FullVelocityTM SYBR Green QPCR Master Mix was from Stratagene. Taq DNA Polymerase 
(5 U/µl) and 10×buffer with MgCl2 were from Genscript. 10 mM dNTP mix and 100bp DNA 
ladder plus were from Fermentas. Low molecular weight DNA ladder was from New 
England Biolabs. Alpha-P32-dATP (3000 Ci/mmol) was purchased from MP Biomedicals. 
LPS (E. coli, 055:B5), endotoxin-free PBS, sigmacote and bovine serum albumin (BSA) 
were obtained from Sigma. Aquacide II (MW=500 kDa) was from Calbiochem. The semi-
permeable dialysis membrane (MWCO=12-14 kDa) was from Spectrum. The recombinant 
enterokinase kit and EKapture agarose were from Novagen. The 3H-Arachidonic acid (98.60 
Ci/mmol) ([5, 6, 8, 9, 11, 12, 14, 15-3H (N)]-), arachidonic acid and Lipidex 1000 were from 
Perkin Elmer. The 1.5 ml siliconized microcentrifuge tubes were purchased from United 
Laboratory Plastics. The HRP conjugated secondary goat anti-rabbit antibody was from 
Santa Cruz Biotechnology. The flat-bottom 96 well ELISA Nunc MaxiSorpTM plates, 
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10×ELISA coating buffer and 1×TMB substrate solution were from eBioscience. The 
Tween-20 was from Fisher Biotech.  
 
RNA from LPS-stimulated (stimulated with 10 ng/ml LPS for 6h) and non-LPS  
stimulated primary spleen cells (2×106 cells), was prepared and stored in RNALater for use. 
These were used as positive and negative controls to test cytokine primers and the cells were 
gifts from Dr. Mike J. Wannermuehler (Dept. of Veterinary Microbiology & Preventive 
Medicine, Iowa State University, Ames, IA). His graduate student, Zhiping Liu, made the 
cell preparations. Normal Balb/c mice were purchased from Laboratory of Animal Resources 
(Veterinary Medicine School, Iowa State University, Ames, IA). Lcn2-deficient mice were 
gifts from Dr. Thorsten Berger and Dr. Tak Mak (The Campbell Family Institute for Breast 
Cancer Research and the Ontario Cancer Institute, Toronto, Canada). The original genetic 
background of the Lcn2-deficient mice was FVB, which was backcrossed to Balb/c mice for 
6 generations. Wild type controls were all Lcn2-deficient littermates. All animals were bred 
at the animal facility of Molecular Biology Building basement, Iowa State University. H & E 
and Giemsa wax blocks and slides were made by the Histopathology Services of Veterinary 
Medicine School of Iowa State University.  
 
The primers used for animal genomic status testing, multiplexed RT-PCR and real- 
time RT-PCR are as follows. 1) For Utc wild type testing: a 283bp amplicon produced by 
using primers 1089 (sense: GGTTTGGTGGCAGGCTATTA) and 1090 (antisense: 
CAGAGTGGCTTTCCCCATAA). 2) For Utc mutant allele testing: a 528bp amplicon 
produced by using primers 1091 (sense: TGCTCCTGCCGAGAAAGTAT) and 1092 
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(antisense: CTCTTCCTCCTCCAGCACAC). 3) For cyclophilin: a 215bp amplicon 
produced by using primers 1020 (sense: CTTTTCGCCGCTTGCTGCA) and 1021 (antisense: 
ACCACCCTGGCACATGAATCCT). 4) For GAPDH: a 211bp amplicon produced by using 
primers 1030 (sense: TGACATCAAGAAGGTGGTGAAGCA) and 1031 (antisense: 
GGTCCACCACCCTGTTGCTGT). 5) For Utc: a 170bp amplicon produced by using 
primers 1095 (CAATGTCACCTCCATCCTGGTCA) and 1096 (GCGAACTGGTTGTAGT 
CCGTGGT). All these primers were previously chosen and optimized for PCR by Wei Zhao. 
6) For TNF-α: a 175bp amplicon produced by using primers 2501 (sense: CATCTTCTCAA 
AATTCGAGTGACAA) and 2502 (antisense: TGGGAGTAGACAAGGTACAACCC). 7) 
For IL-1β: a 152bp amplicon produced by using primers 2503 (sense CAACCAACAAGTG 
ATATTCTCCATG) and 2504 (antisense: GATCCACACTCTCCAGCTGCA). 8) For IL-6: 
a 141bp amplicon produced by using primers 2505 (sense: GAGGATACCACTCCCAACAG 
ACC) and 2506 (antisense: AAGTGCATCATCGTTGTTCATACA). All these cytokine 
primer sequences were taken from the literature (Overbergh, Giulietti et al. 2003) and 
synthesized by the DNA Sequencing and Synthesis Facility (Iowa State University, Ames, 
IA).  
 
METHODS 
Mouse intranasal administration: LPS was dissolved in endotoxin-free PBS and 1,  
2 or 5 µg/µl LPS stock solutions were prepared. 250 µl/tube aliquots were stored at -20oC 
until use. The LPS was warmed to 37oC in a water bath before being applied to animals. 
Mice were anesthetized with CO2 to a wobble walk, and then taken out of the cage. 0, 0.4, 2, 
or 4 mg/kg of LPS in endotoxin-free PBS was applied into the nasal cavity using a 20 or 200 
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µl pipette with a 20 or 200 µl gel loading tip. Each nostril received half of the liquid volume. 
Each mouse was placed back in the cage for the 6 h treatment. Like-treated mice were put 
together in the same cage. To avoid LPS contamination of the PBS group, the PBS-group 
was treated first then put back into the breeding room before the LPS-group was treated. The 
LPS-treated group was kept in the user room. After 6 h, the animals were sacrificed by 
exposure to an overdose of CO2. Blood was collected by cardiac puncture. Lung lavage fluid 
was collected as description in lung lavage section. Lung and liver samples were fixed in 
Carnoy’s fixative (60 ml absolute ethanol, 30 ml chloroform, 10 ml glacial acetic acid) for 4 
h at room temperature, and then washed in 75% ethanol three times. The tissues were soaked 
in 75% ethanol overnight for embedding, cutting, and routine H & E and Giemsa stains 
(Service of Veterinary Pathology, Iowa State University, Ames, IA). The remaining lung, 
liver and other organs (heart, spleen, colon, and kidney) were cut into small pieces, snap-
frozen in liquid nitrogen, and stored at -80oC for later total RNA isolation.   
 
Serum separation: Whole blood was collected via cardiac puncture and placed into  
1.5 ml centrifuge tubes. The blood was allowed to clot at room temperature for 2 h, and then 
incubated at 37oC for 1 h. The clot was dislodged by gently tapping the tube then left at 4oC 
overnight. The serum was separated from the clot by centrifugation at 10,000×g for 15 min at 
4oC. The supernatant was transferred into a fresh tube and spun again at 10,000×g at 4oC for 
15 min. The serum was collected, aliquoted into a 100 µl/tube and stored at -80oC until use.    
    
Lung lavage: The PE90 polyethylene tubing (Becton Dickison) was cut to pieces  
  
39 
approximately 1 inch long with one end cut at an angle. The straight cut end of the PE90 
tubing was placed into a butterfly catheter (25GA×3/4", Terumo). The catheter needle was 
cut off and discarded. The angle cut part of the PE90 tubing was then inserted into the mouse 
trachea. A 10cc syringe was placed in a clamp on a ring stand. A 3-way stopcock (Medex) 
was attached to the end of the syringe to control the saline to flow. The end of the butterfly 
catheter was connected to the stopcock. The syringe was filled with approximate 10 ml saline. 
The animal was euthanized by an overdose of CO2, then taken out of the cage and placed 
spread-eagle on its back on the bench. The mouse’s body cavity was carefully cut open 
beneath the diaphragm and the diaphragm was cut away. Care was taken not to puncture the 
lung to ensure that the lung would expand during the lavage. The mouse was carefully cut in 
the neck region to expose the trachea and the nearby muscle was removed so that the tracheal 
ring could be seen. A scalpel was used to make a small nick in the trachea that was large 
enough to insert the angle cut end of the PE90 tubing. The tubing was marked with black at a 
location 0.5 cm from the tip and inserted into the trachea, making sure that the mark could be 
seen during lavage to control the depth of the tubing insertion. The trachea was irrigated with 
500 µl of saline using gravity at 25 cm to promote liquid flow into the lung. The tubing was 
removed from the stopcock and placed in a 15 ml tube for lavage fluid collection. The tube 
was placed lower than the level of the mouse to allow the fluid to flow from the rings into the 
collection tube. The lavage was repeated 500 µl at a time for a total of 4 to 5 ml and stored at 
-80oC.       
 
Total RNA isolation: Frozen lung or liver tissue pieces that had been stored at -80oC  
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were homogenized in 1 ml TRIzol reagent per 30-100 mg of tissue, using a power 
homogenizer (Tekmar’s TISSUMIZER). The homogenized samples were incubated for 5 
min at room temperature to permit dissociation of nucleoprotein complexes. 0.2 ml of 
chloroform was added per 1 ml TRIzol reagent. The tubes were sealed and shaken vigorously 
by hand for 15 seconds and incubated at room temperature for 2 min. Then the samples were 
centrifuged at 10,000×g for 15 min at 4oC. Following centrifugation, the aqueous phase was 
transferred to a fresh tube and 0.5 ml of isopropyl alcohol was added to precipitate the RNA. 
The samples were incubated at room temperature for 10 min and centrifuged at 10,000×g for 
10 min at 4oC. The supernatant was removed and the RNA pellet was washed with 1 ml of 
75% ethanol, which had been made with DEPC-treated H2O. The samples were mixed by 
vortexing and spun at 7000×g for 5 min at 4oC. The ethanol was removed and the RNA pellet 
was air dried for 10 min. The RNA should not be completely dried as this made it more 
difficult to redissolve the pellet. The RNA was dissolved in DEPC-treated H2O and incubated 
for 10 min at 55oC. The total RNA was stored at -80oC.  
 
cDNA preparation: 0.1 µg/µl of total RNA, DNase I reaction buffer (20 nM Tris- 
HCl pH 8.4, 2 mM MgCl2 and 50 mM KCl), 0.1 U/µl of DNase I, and DEPC-treated water 
were assembled into an RNase-free tube on ice. The tube was incubated for 15 min at room 
temperature. The DNase I was inactivated by adding 2.5 mM EDTA to the reaction mixture 
and heated for 10 min at 65oC. For reverse transcription, 25 µg/ml of oligo(dT)18, 
(synthesized by the DNA Sequencing and Synthesis Facility. Iowa State University, Ames, 
IA), 0.1 µg/µl of total RNA from above and 0.5 mM of dNTP mix (0.5 mM of dATP, dGTP, 
dTTP and dCTP separately) were assembled in a tube. The mixture was heated at 65oC for 5 
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min and quickly chilled on ice. The contents of the tube were collected by brief 
centrifugation and then first-strand buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM 
MgCl2) and 10 mM DTT were added. The contents of the tube were gently mixed and 
incubated at 42oC for 2 min. 10 U/µl SuperScriptTM II reverse transcriptase was added and 
mixed by pipetting gently up and down. The sample was incubated at 42oC for 50 min and 
the reaction was inactivated by heating at 70oC for 15 min. The cDNA was then ready to be 
used as a template for PCR amplification.     
 
Mouse genomic status test: About 0.5 cm in length was cut from tails of 10-14 day  
old pups. The tail piece was placed in a cryogenic vial that contained 300 µl of lysis mix (10 
mM Tris pH 8.0, 50 mM KCl, 2 mM MgCl2, 0.45% NP-40, 0.45% Tween-20, 100 µg/ml 
proteinase K). The tube was incubated overnight with gentle rocking at 55oC, and then spun 
at 12,000×g for 20 min at 4oC to pellet precipitates. The supernatant was transferred into a 
fresh tube and 300 µl of isopropanol was added. The contents were gently and thoroughly 
mixed, then centrifuged at 12,000×g for 25 min at 4oC again to pellet the DNA. The 
supernatant was discarded and the pellet was washed twice with 1 ml of 70% ethanol then air 
dried for 5 min. The DNA was dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 
7.0) and heated at 55oC for 10 min to promote solubilization. This genomic DNA was stored 
at -80oC. The PCR mixture was assembled in a total 25 µl reaction volume: 50 mM KCl, 10 
mM Tris-HCl pH 9.0, 1.5 mM MgCl2, 0.1% Triton X-100, 0.2 mM dNTPs, 0.05 U/µl Taq 
DNA Polymerase, 300 nM oligos 1089/1090, 1000 nM oligos 1091/1092 and 1 µl of the 
genomic DNA preparation from above. The PCR program was run at 95oC×10’ first, then for 
a total of 30 cycles at 95oC×30’’, 60oC×30’’, 72oC×45’’ with a final extension at 72oC×15’. 
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The PCR products were resolved by electrophoresis through a 1.6% agarose gel that 
contained 5 µg/ml of ethidium bromide and run in TAE buffer (90 mM Tris base, 0.9 M 
boric acid, 0.1 M EDTA, pH 8.0) at a constant 100 volts for 45 min.  
 
Multiplexed RT-PCR and PAGE (polyacrylamide gel electrophoresis, 10%, run on  
a sequencing gel plate set under 1800 volts): Before performing multiplexed RT-PCR, the 
primer pairs for cyclophilin (1020/1021), TNF-α (2501/2502), IL-β (2503/2504) and IL-6 
(2505/2506) were tested by PCR. The PCR program was run in a 25ul PCR reaction volume 
for 94oC×10’ first, then a total 30 cycles at 94oC×15’’, 60oC×1’, 72oC×1’ and final extension 
at 72oC×15’. The PCR products were resolved by electrophoresis through a 1.5 to 3% 
agarose gel that contained ethidium bromide and run in TAE buffer at a constant 100 volts 
for 50 min. The DNA bands were visualized using a transilluminator. Primer concentrations, 
Mg2+ concentrations and the PCR number of cycles were also optimized for multiplexed RT-
PCR. Optimal concentrations of primer pairs, Mg2+ and 1 to 5 µl of mouse lung and liver 
cDNA samples were added to a 25 µl PCR reaction mixture, followed by the addition of 3 
pmol/µl P32-ATP. PCR was run using the same program for 33 cycles and the PCR products 
were resolved through a 10% acrylamide gel under constant 1800 volts for 3 to 6 h in TBE 
buffer (40 mM Tris acetate, 1 mM EDTA, pH 8.0). The gels were dried on gel dryer (Model 
583, Bio-Rad) for 1 h and gel images were captured by Typhoon 8600 Imager (Molecular 
Dynamics, Amersham Pharmecia Biotech. The Protein Facility of Iowa State University, 
Office of Biotechnology, Ames, IA). The densities of the bands were quantified using 
ImageQuant software. The data for the levels of cytokine mRNAs were normalized to the 
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data for levels of cyclophilin mRNA in the same samples and statistical analysis was applied 
as described in a later section. 
 
Real-time RT-PCR: The expression levels of GAPDH, TNF-α, IL-6 and Utc from  
mouse lungs and livers were measured by real-time RT-PCR (Bio-Rad MJ Research DNA 
thermocycler). The standards of GAPDH, TNF-α, IL-6 and Utc were made by PCR 
amplification using optimal multiplexed RT-PCR conditions. For each cDNA, the regions of 
gel containing the amplified DNA bands were cut from the gel, pooled and recovered by 
using a QIAquick gel extraction kit. The recovered DNA was quantified and the appropriate 
dilutions prepared to make a standard curve. Each primer concentration of GAPDH, TNF-α, 
IL-6 and Utc was also optimized for real-time RT-PCR. In a total 20 µl reaction volume, 
50% FullVelocityTM SYBR Green QPCR Master Mix, primer pairs at the optimal 
concentrations, 1 µl of tissue cDNAs were assembled. The PCR program was run at 95oC×5’ 
first, then for a total of 40 cycles at 95oC×10’’, 60oC×30’’ based on the FullVelocityTM 
SYBR Green QPCR master mix instruction. The data for the levels of cytokine and Utc 
mRNAs were normalized to the data for the levels of GAPDH mRNAs in the same samples 
and statistical analysis was applied as described next.  
 
Statistical analysis: All data from either multiplexed or real-time RT-PCR was log  
transformed (base 10) for analysis. The data was then analyzed by ANOVA using a general 
linear model (PROC GLM in SAS) that included the factors of treatment, genotype, and 
interactions between treatment and genotype. Least squares means and standard errors were 
determined using LSMEANS and STDERR statements in PROC GLM. Means were 
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compared either by the Tukey-Kramer (TK) method to adjust multiple comparisons or 
without multiple comparisons, and significant differences were determined to be when P < 
0.05.   
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RESULTS AND DISCUSSION  
 
MOUSE GENOMIC STATUS TEST 
Toe or tail genomic DNAs from mouse pups of 10 to 14 days were PCR amplified  
using a combination of Utc wild type primer pairs 1089/1090 and Utc mutant allele primer 
pairs 1091/1092. A 283bp amplicon was produced by 1089/1090 and a 528bp amplicon was 
produced by 1090/1091 under optimized PCR parameters. If the mouse was a Utc wild type, 
only the 283bp PCR product should be observed. If the mouse was a Utc knockout, only the 
528bp PCR product should be observed. If the mouse were a heterozygote, both 283bp and 
528bp amplicons should be seen on the gel. As an example mouse 4712.11 was a Utc 
knockout; mice 4712.12, 4712.15, 4712.16, 4712.17, 4712.18 and 4712.20 were wild type 
littermates; mice 4712.13, 4712.14 and 4712.19 were heterozygotes (Fig. 4). Three weeks 
later, after the genomic status of mice was identified, the pups were separated from their 
mothers and maintained in a group. Usually mice with the same genetic status were kept in 
the same cage.     
 
PCR CONDITION OPTIMIZATION 
Three pro-inflammatory cytokines, TNF-α, IL-1β and IL-6, were chosen as  
inflammation indicators because they have been well studied and demonstrated to be 
associated with inflammation. Cytokine sequences were used that had originally been 
designed for real-time PCR, using TaqMan probes (Overbergh, Giulietti et al. 2003). Each 
primer was assigned a number for lab records. 2501/2502, primer pair for TNF-α, gave a 
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175bp PCR amplicon. 2503/2504, primer pair for IL-1β, gave a 152bp PCR amplicon. 
2505/2506, primer pair for IL-6, gave a 141bp PCR amplicon under optimal PCR conditions.  
 
To test the applicability of these primers under our laboratory conditions, spleen  
cDNAs from LPS-treated normal Balb/c mice or Utc knockouts were used as templates (See 
Table 1). When a 200 nM TNF-α primer pair was used, 175bp PCR amplicons were detected 
from all spleen samples of m227.3, m230, m231, m234 and m235 (Fig. 5A). The bands were 
not very bright, which may have been caused by either the low level of TNF-α mRNA in the 
original RNA samples or that the PCR conditions needed to be further optimized (for 
example, the primer or Mg2+ concentration). But the correct amplicons demonstrated the 
applicability of TNF-α primer pair. A similar experiment was done for IL-β, in which 200 
nM of IL-1β primer pair 2503/2504 was used and 152bp PCR products were detected from 
all chosen samples (Fig. 5B). This result confirmed the applicability of IL-1β primer pair.  
 
IL-6 mRNA could not be detected in any of the chosen samples including spleen  
samples used for TNF-α and IL-β, and some 11-19 day mouse placenta samples. Initial 
studies suggested that this IL-6 primer pair did not work well as the TNF-α or IL-β primers. 
Several other IL-6 primer sequences identified from other publications were synthesized, 
among which the amplicons ranged from 70bp to 500bp. None of them demonstrated the 
correct PCR products (data not shown). Then we suspected that maybe the level of IL-6 
mRNA expression was very low in all the tested samples. One problem was that there was no 
IL-6 standard sample (tissue, cells, total RNA or cDNA) in the lab that could be used as 
control. It was difficult to tell whether it was the problem of the primers, the PCR conditions 
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or because of the low expression of IL-6 in the chosen samples. To resolve this problem, 
LPS-stimulated and non-LPS stimulated mouse primary spleen cells were obtained as a gift 
from Dr. Mike J. Wannermuehler. The Wannermuehler lab successfully detected IL-6 
mRNA expression using real-time PCR from LPS-stimulated primary spleen cells while 
using non-LPS stimulated spleen cells as control. The total RNAs from these spleen cells 
were isolated and reverse transcripted to cDNAs. The correct TNF-α, IL-1β and IL-6 
fragments were all successfully detected from LPS-stimulated spleen cell mRNA using 200 
nM primer pairs of 2501/2502, 2503/2504 and 2505/2506 (Fig. 5C). No bands were detected 
using other IL-6 primer pairs other than the 2505/2506 pair (data not shown).  
 
Once all the three cytokine primer pairs were demonstrated to work individually, they  
were tested for their ability to work together in multiplexed RT-PCR. In order to get the best 
multiplexed RT-PCR result, optimization of individual PCR condition was performed for 
each cytokine. cDNA from m230 spleen was used as a template for TNF-α and IL-1β and 
cDNA from LPS-stimulated primary spleen cells was used as a template for IL-6. First the 
primer concentration was optimized by testing the concentrations at 200, 400 and 800 nM 
with the Mg2+ concentration constant at 1.5 mM of (Fig. 6A). The higher concentration gave 
the brighter band for all three cytokines. Next, three Mg2+ concentrations (1.5, 3.0 and 6.0 
mM) were tested with cytokine primer concentrations constant at 400 or 800 nM. Within the 
tested range, the Mg2+ concentration had little influence on the PCR amplification (Fig. 6B 
and 6C). To further confirm the results, different templates were chosen. cDNA from non-
LPS stimulated spleen cells was used for TNF-α and IL-1β and cDNA from LPS stimulated 
spleen cells was used as a template for IL-6. The choice of 1.5 mM Mg2+ concentration was 
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based on the results of Fig. 6B and 6C. The best amplicon bands were seen at 800 nM primer 
concentration for all three cytokines (Fig. 6D). Therefore the optimal PCR parameters were 
1.5 mM Mg2+ and 800 nM primer concentrations for each cytokine. Cyclophilin was selected 
as the internal control gene because it was reported to be a better control gene than other 
genes, such as like β-actin and GAPDH (Pachot, Blond et al. 2004). The cyclophilin primer 
concentration was optimized in a similar way. The cDNA from m235 spleen was used as a 
template and 200, 400 and 600 nM primer concentration were tested. Even at the lowest 
tested primer concentration 200 nM, very bright cyclophilin fragments were seen on the gel 
(Fig. 6E). In summary, 1.5 mM Mg2+, 800 nM cytokine primers and 200 nM cyclophilin 
primers were set as the initial optimal multiplexed RT-PCR parameters.      
 
MULTIPLEXED RT-PCR AND PAGE 
The purpose of using this method was to do a quick screen to identify which mRNAs  
were the most interesting one to focus on. The first multiplexed RT-PCR and polyacrylamide 
gel result is shown in Fig. 7A, which shows very distinct amplified bands for each cDNA 
template. This meant that the multiplexed RT-PCR worked well using the initial optimal 
parameters developed for the individual primers. The distance between each band was 
sufficient to allow the bands to be separated and quantified using ImageQuant image analysis 
software. The gel loading volume was also optimized in this experiment. 1, 2 and 3 ul 
loading volumes were tested to see which one would give the best band visualization. There 
was very little effect on the ability to measure the PCR amplification products by changing 
the loading volumes. Therefore 2 ul was used for future studies because it allowed more 
precise control of volume delivery and it was not too large a volume to risk spilling when 
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loading. This loading volume (2 ul) was used in all experiments except when otherwise 
stated. cDNAs from m235 spleen and LPS-stimulated mouse primary spleen cells were used 
as templates. No amplicon was seen from the “no template” control (NTC). Because there 
was no commercially available radiolabelled DNA marker, cyclophilin, TNF-α, IL-1β and 
IL-6 standard fragments were PCR amplified and run simultaneously with the samples to be 
used as molecular mass standards. The positions of the four standards on the gel are indicated 
by the arrows on the right side of Fig. 7A. The cyclophilin bands showed a little too dark 
compared with cytokine bands in Fig 7A. Therefore, a lower cyclophilin primer 
concentration of 100 nM was tested using cDNAs from m227.3 and m231 spleens as 
templates with other parameters the same as in Fig 4A (Fig. 7B). Under these conditions, less 
dark cyclophilin bands were observed and the cytokines showed the expected amplicons with 
good separations (Fig. 7B). These results demonstrated that multiplexed RT-PCR and PAGE 
was a reliable and repeatable method. Unless otherwise stated, 100 nM cyclophilin primers 
were used in all multiplexed RT-PCR. 
  
Initially, 35 PCR cycles were used for multiplexed RT-PCR. To minimize the effect  
of PCR saturation, the influence of PCR cycle was also investigated. cDNAs from lung and 
spleen were used as PCR templates, and 20 and 30 PCR cycles were run in tandem. In Fig. 
7C, no amplicons could be seen at 20 cycles for both samples. With 30 cycles, clear bands 
were observed for all cytokines. But compared with previous experiments using 35 cycles, 
the intensities of the bands were weaker at 30 cycles. Therefore 33 cycles were chosen as a 
compromise between 30 and 35 cycles. In summary the final optimal conditions chosen for 
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multiplexed RT-PCR and PAGE were: 1.5 mM Mg2+, 100 nM cyclophilin primers, 800 nM 
cytokine primers, 2 ul gel loading volume, and 33 PCR cycles.  
 
Fig. 8A and 8B show two representative images of the samples on PAGE out of more  
than 20 gels run for multiplexed RT-PCR. In both gels, clear bands and good separations 
were observed. In order to load more samples on each gel but to avoid contaminating 
neighboring wells, samples were loaded in two batches on one gel with the gel run for 2.5 h 
after loading the 1st batch and before loading the 2nd. The second batch of samples was 
loaded in alternate lanes to the first batch. After running, each gel was dried, exposed to a 
phosphor screen, and the relative exposure values were read using a phosphor imager. The 
density of each band was quantified using ImageQuant software. After the gel background 
value was subtracted from all bands, the cytokine values were normalized to the cyclophilin 
values in the same lane. The ratio of each cytokine value to the cyclophilin value in the same 
lane was used for further analysis. The three cytokine signals from both mouse lung and liver 
samples were measured using multiplexed RT-PCR and PAGE. Most mice used in the 
experiments were male mice. Most mice were 7-8 weeks old with only a few mice of 11 or 
14 weeks in age.  
        
Table 2 summarizes the multiplexed RT-PCR data. Gray highlighted values for the  
lung were not used for the final data analysis because the values were either extraordinarily 
high or below zero. Some other relatively high values were also seen. We thought this might 
be caused by one or two PCR runs in which cyclophilin was not amplified properly, which 
led to higher normalized ratios relative to others. We also recognize that this experimental 
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system of multiplexed RT-PCR is likely to give high standard deviations because it is not a 
quantitative method like real-time PCR that utilizes a standard curve.  
 
Six hours were used for the animal treatment because it has been reported to be long  
enough to initiate early stage inflammation symptoms (Smith, Skerrett et al. 1998; Skerrett, 
Martin et al. 1999; Glasgow, Ramachandran et al. 2005). In these experiments, the animals in 
the “no treatment” group were directly taken out of their cages and sacrificed by CO2 instead 
of undergoing CO2 anesthesia first followed by a 6 h recovery as LPS or PBS treated animals 
experienced. Therefore, the “no treatment” group is considered as an “imperfect” control. 
The “perfect” control should be CO2 anesthesia first followed by a 6 h recovery, then an 
overdose CO2 sacrifice exactly as the LPS and PBS treated-mice underwent. Because of this 
reason, more focus in the analysis was paid to the PBS control. Therefore, the statistical 
comparisons for LPS treatments were made vs PBS, not vs NT (no treatments). Furthermore, 
because the LPS were dissolved in endotoxin-free PBS, the ratio of LPS vs. PBS was a more 
appropriate means of judging the effect of LPS on the mice. For multiplexed RT-PCR, the 
data was analyzed by normalizing higher doses of LPS (2 and 4 mg/kg) to the lowest LPS 
dose, 0.4 mg/kg to give a clearer trend. 
 
Figure 9 shows the effect of LPS on TNF-α, IL-1β and IL-6 mRNA expression in KO  
and WT lung and liver. An obvious increase in the level of three cytokine mRNAs in both 
KO lung and liver was seen, and the three cytokine mRNAs showed a significant difference 
between the 4 mg/kg and 0.4 mg/kg treatments. There was little increase of these mRNAs in 
the WT and no significance was observed between any treatments in the WT samples. In the 
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lung, significant differences were also found for these three cytokine mRNAs in comparing 
the 4 mg/kg KO vs 4 mg/kg WT (Fig. 9A). But in the liver, there was no significant 
difference observed between the KO and WT (Fig. 9B).    
  
Some decreases compared to the controls were observed in the KO at 2 mg/kg in the  
lung and some decreases in the WT at 2 mg/kg in the lung and liver. We believed this is an 
artifact because fewer mice were used for this dose (only two mice for both KO and WT), 
which resulted in bigger errors. Another interpretation could be that cyclophilin is not a good 
internal control in this study because it has been reported to be a pro-inflammatory cytokine 
(Sherry, Yarlett et al. 1992; Jin, Lungu et al. 2004). Cyclophilin expression level may be 
changed due to the experimental treatment and this would cause changes in the estimate of 
relative cytokine mRNA levels.  
 
Together, the discussions above and the results of the analysis of the multiplexed RT- 
PCR data (Fig. 9) suggest that Utc might suppress cytokine expression in the lung and liver. 
This is consistent with our hypothesis that Utc is anti-inflammatory.   
 
REAL-TIME RT-PCR 
In order to obtain quantitative data, real-time RT-PCR was employed to measure the  
cytokine expression levels in the lung and liver. The suspicion that cyclophilin might not be a 
good internal control made us decide to use GAPDH as the internal control for real-time RT-
PCR (Bustin 2000; Vandesompele, De Preter et al. 2002; Garcia-Vallejo, Van Het Hof et al. 
2004). We also added Utc to the investigation list, and anticipated that the Utc expression in 
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WT littermates should be increased in response to LPS challenge. To reduce the complexity 
of experiments, only TNF-α and IL-6 were chosen for analysis by real-time RT-PCR. To 
establish standard curves for GAPDH, Utc, TNF-α and IL-6, the four genes were amplified 
from m235LG+/+, m256LG+/+ or m258LG-/- cDNAs that contained TNF-α and IL-6 cDNA 
based on multiplexed RT-PCR results. GAPDH was expected to be amplified easily from any 
sample and Utc was expected to be able to be amplified from wild type samples. In addition 
to preparing DNA standards, different concentrations of primers were tested to decide at 
which concentration, the best bands with the least amount of primer dimers were obtained. 
Three different primer concentrations were tested for each cDNA: 200, 400 and 800 nM. 
Fragments with correct sizes were amplified for all primer sets (Fig 10A-E). Most of them 
only showed weak primer dimer at 800 nM. Therefore using concentrations lower than 800 
nM for real-time RT-PCR should be safe to avoid primer dimers. Next, these cDNA 
amplicons were resolved on agarose gels, extracted, and individual DNA was pooled and 
concentrated. The recovered DNA for each gene is shown in Fig. 10F. Bright bands were 
seen for all four cDNAs with correct sizes. The concentrated DNAs were then diluted to 
different concentrations to prepare real-time RT-PCR standards. Mostly, a concentration 
dilution series of 10-1, 10-2, 10-3, 10-4, 10-5, 10-6 ng/ml were used for standards. A standard of 
10-7 ng/ml was used sometimes when a sample contained a low concentration of DNAs. This 
was to make sure the sample data was in the range of standard curve range. Primer 
concentrations used for GAPDH, Utc, IL-6 and TNF-α were varied from 100 nM to 500 nM 
based upon the sample cDNA amount and no primer dimers were detected at any 
concentration tested.  
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Duplicates were performed for all samples tested in real-time RT-PCR. Table 3  
contains the complete set of lung and liver real-time RT-PCR data. In the analysis of all WT 
data, the results showed that LPS induced Utc expression in the lung and liver (Fig. 11A). In 
the liver, a 44.6 fold of Utc increase was observed at 4 mg/kg LPS compared with PBS and 
this increase was statistically significant. In the lung, around a 2 fold increase of Utc was 
observed at 2 and 4 mg/kg of LPS treatments compared with PBS, but none of these was 
statistically significant. A similar trend was observed in the analysis of younger mouse (7-8 
week old) data (Fig. 11B), 2 and 4 mg/kg of LPS treatments caused around 2 fold of Utc 
increase in the lung, but none of these difference was statistically significant. In the liver, less 
dramatic Utc increases were found; around 9 fold of increase was detected at 2 mg/kg LPS 
and a 7 fold of increase were observed at 4 mg/kg LPS treatment. Both these increases were 
statistically significant. For the older mice (11 or 14 week old), only the effect of 4 mg/kg 
LPS vs PBS was studied. In the analysis of older mouse data, around 5 and 74 fold of Utc 
increases were detected in the lung and liver respectively (Fig. 11C). Interestingly, none of 
these two increases was significant. This might be because that 5 out of the samples for 7 
older WT mice used for the 4 mg/kg of LPS treatment were from a lab mate. There were 
differences in the treatment of the mice and in the preparation of the samples. Either of these 
could be responsible for the different results.          
 
In analyzing the cytokine mRNA expression in KO and WT lung and liver from all  
the mouse data, the sample for the 2 mg/kg treatment for WT was removed from the 
calculations because only a single data point was available, which would cause inaccurate 
analysis. In the KO lung, both TNF-α and IL-6 mRNA showed increases at the higher LPS 
  
55 
dose, and this wasn’t detected in the WT lung. For both TNF-α and IL-6 in the lung, 
differences at 4 mg/kg of LPS between KO and WT were statistically significance (Fig. 12A). 
In the liver, IL-6 increased 73 fold and TNF-α increased 7 fold in the KO. Little increase of 
either was seen in the WT. Both TNF-α and IL-6 increases had statistical significance 
comparing 4 mg/kg of LPS with PBS in KO. IL-6 was statistically significant comparing KO 
and 4 at 4 mg/kg (Fig. 12B). In the analysis from younger mice, the obvious increases in 
cytokines in the lung that were seen with the older mice were absent. The data for the KO is 
the same as for the WT data and no statistical significance was observed for any comparison 
(Fig. 13A). In the liver, both cytokines showed less dramatic increases at 4 mg/kg, 7 for IL-6 
and 6 for TNF-α when compared with PBS than for the older animals. The WT had no 
apparent increase as usual. No significance was observed for any comparison within this 
younger group data (Fig. 13B). In the data analysis for the older mice, only a comparison 
between KO and WT at 4 mg/kg was made. In the lung, 222 fold of IL-6 increase was 
detected and 11 fold of increase of TNF-α was seen. Both of these increases were statistically 
significant (Fig. 14A). In the liver, TNF-α didn’t show a detectable increase at 4 mg/kg 
comparing KO and WT, but IL-6 demonstrated around 226 fold of increase, which was 
statistical significant (Fig. 14B).    
 
H & E STAIN 
H & E sections were all reviewed by one pathologist (Dr. Mark R. Ackermann) and  
the scoring system and scoring record are displayed in Table 4. Most of the sections lacked 
macrophages, mast cells and neutrophils that are known to play roles in the early 
inflammatory phase (Singh, Pearce et al. 2004; Fujiwara and Kobayashi 2005; Fukuishi, 
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Yoshioka et al. 2005; Komatsu, Koyama et al. 2006). Fig. 15A is a liver control section and 
Fig. 15B is a lung control section for which the sample is m252, a PBS treated 7-week old 
knockout. No remarkable lesions were observed for either lung or liver. Neutrophils and 
macrophages were only observed in the sections of m256+/+, m257+/+ (11-week WTs 
treated with 4 mg/kg of LPS) and m258-/-, m259-/-, m260-/- (14-week old KOs treated with 
4 mg/kg of LPS). Fig. 15C is the liver section of m256+/+. Neutrophils are seen in the blood 
vessel and it is scored 1. Fig. 15D is the lung section of m256+/+. Increased neutrophils in 
capillaries/septa/ vessels were observed and it was scored 1. Fig. 15D is the lung section of 
m259-/- and an aggregate of neutrophils is observed around capillary. This section has the 
most neutrophils among all slides and it was scored 2. 
 
The neutrophil infiltration observed in sections of 4 mg/kg of LPS treated older mice  
(either 11 or 14 week old) matched the dramatic cytokine mRNA increases measured by both 
multiplexed RT-PCR and real-time RT-PCR. The less dramatic increases of neutrophils and 
cytokines in the samples from younger mice could be interpreted that 6 h was still a little 
early in the time course of the response. Longer time courses, 8 h, 12 h or 20 h should be 
studied. Our current results also indicated that it was possible that Utc might have more 
significant effects on older mice than younger ones. This could be explained by the 
possibility of immune system immaturity of younger mice compared with older mice 
although mice were regarded as sexual maturity after 5 weeks.  
 
As the initial experimental design of this project, it was planned that only 8-week old  
  
57 
mice would be used because mice are adults at this age. During the project, some older mice 
(11 and 14 weeks old) became available from breeding and they were also used in the study. 
When first analyzing the data, we did not distinguish the age difference because we didn’t 
expect that there would be much difference between the two groups. But after analyzing the 
multiplexed RT-PCR data analysis, we noticed that the three 14-week old knockouts, m258-
/-, m259-/- and m260-/- contributed a lot to the final results, especially to the difference in 
IL-6 induction between KO and WT. This was confirmed by real-time RT-PCR later. 
Neutrophil infiltration into the lung and liver was only observed in samples from m256+/+, 
m257+/+, which were the 11-week old WT littermates treated with 4 mg/kg of LPS and 
m258-/-, m259-/- and m260-/-. Although these two groups of mice were shown to have 
neutrophil infiltration, abnormal and sick behaviors were only observed for the KO animals, 
m258-/-, m259-/- and m260-/-, after they were treated with 4 mg/kg of LPS (Video). The 
three mice tended to huddle together, trembled, moved less, and breathed more deeply 
throughout the 6 h recovery stage. More seriously, m259-/- died right at 6 h before sacrifice. 
No similar abnormal behaviors were observed for the younger mice with any treatment. 
Considering the differences observed for these three 14-week old knockouts compared to the 
8-week old animals, we thought age might be an important variable in response to LPS 
challenge. Therefore in the real-time RT-PCR, the analysis was done for all mice and for 
younger mice and older mice separately.    
 
Taken together the data analysis from both multiplexed RT-PCR and real-time RT- 
PCR demonstrated a similar cytokine increase trend in KO mice but not in WT littermates 
when mice were intranasally challenged with LPS. Using real-time RT-PCR, Utc mRNA 
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expression was found to be increased in response to LPS in the WT animals. Whether age is 
an important variable or not still needs further investigation. In summary, the current results 
support our hypothesis that Utc might play anti-inflammatory role in vivo by suppressing 
cytokine expression.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Date analysis from multiplexed RT-PCR (Fig. 6A & 6B) showed that, in both lung  
and liver, KO mice had significant higher cytokine mRNA expression at higher LPS dose 
with respect to WT animals. At 4 mg/kg LPS does, all three cytokine (TNF-α, IL-1β and IL-6) 
mRNA levels from KO lung demonstrated significant difference compared with the mRNA 
levels from WT mice. This not only supports our hypothesis that Utc is anti-inflammatory 
but also tells us that Utc might play this role by suppressing cytokine expression. The 
multiplexed RT-PCR data analysis suggests an age difference. Therefore, real-time RT-PCR 
data was analyzed based on different age groups. Result of Utc mRNA measurement in all 
WT mice (Fig. 8A) showed higher Utc mRNA expression at higher LPS dose in both lung 
and liver, but only the changes in the liver had significant difference. Similar results were 
obtained from younger mice data analysis (Fig. 8B). Due to the lack of enough older mice for 
all treatments, only NT, PBS and 4 mg/kg of LPS treatments were performed with older WT 
mice. Apparent Utc mRNA increase was observed in both older mouse lung and liver. But 
the increase had no significant difference which might be due to the different sample sources 
(two from me and five from a lab mate, whose data did not fit well with my data). The results 
of cytokine mRNA measurement in all mice showed significant differences between KO and 
WT mice in both lung (Fig. 9A) and liver (Fig. 9B) but the significance was lost from the 
younger mice data analysis (Fig. 10A & 10B). In the older mice, at 4 mg/kg of LPS dose, IL-
6 difference between KO and WT was significant in both lung and liver, and TNF-α was 
significantly different at 4 mg/kg KO vs 4 mg/kg WT in the lung. Basically, the real-time 
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RT-PCR results matched the multiplexed RT-PCR results. In summary, both PCRs showed 
significant cytokine mRNA increase in all KO mice at higher LPS dose and the increase was 
not observed in all WT mice. There might be a difference between younger mice (7-8 week 
old) and older mice (11 or 14-week old), but this needs more investigation.  
 
The results from H & E staining also support the analysis from both multiplexed and  
real-time RT-PCR. Neutrophils were only observed in the slides of 11 or 14-week old mice 
treated with 4 mg/kg of LPS. No apparent neutrophil infiltration was observed in tissue 
sections from other treatments. But there were no obvious differences in neutrophil 
infiltration between KO and WT mice treated the same way, which might imply that 
neutrophil is not the target of Utc. The macrophage is the major cytokine secretion cell type 
(Titov 2003; Fujiwara and Kobayashi 2005). Although very few of macrophages were seen 
in the slides, it is possible that there is enhanced macrophage cytokine secretion ability in the 
KO instead of the increased macrophage numbers contributing to the cytokine increase. 
Macrophages might be the Utc target. In the WT mice, when Utc is present, it might suppress 
the macrophage cytokine producing capability resulting in lower cytokine expression in the 
WT animals as the data from multiplexed and real-time RT-PCR demonstrated. To test this 
possibility, macrophages from lung or liver lavage fluid were collected and cytokine 
measurement in the KO and WT fluids is under investigation by others in the lab. Using 
macrophage cell lines to test the correlation with Utc in vitro is also ongoing. It is also 
possible that not macrophages but other inflammatory cells, such as mast cells, dendritic cells, 
are involved in the cytokine suppression. After studies with macrophages, other cell types 
might be also tested in the future.  
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In addition to testing the role of macrophages in the cytokine suppression in KO mice,  
another thing that needs to be done soon is to use more 14-week old mice treated with 4 
mg/kg of LPS for 6 h to determine if the increased cytokine expression can be repeated and 
the animal’s abnormal behaviors can also be observed.  
 
The lack of neutrophils in most of the slides could contribute to the early time course  
chosen to observe. Longer treatment time, 12 h or 24 h, could use to see if neutrophils could 
be observed from the younger mice or more neutrophil will be seen in older mice.  
 
Cytokine expression was analyzed at the mRNA level in this study.  Protein levels  
should also be studied to see if corresponding cytokine increase could be detected. It is 
possible that the protein level doesn’t match mRNA level well because of the substantial 
post-transcriptional and post-translational regulation of protein levels. But the data from 
analysis of the protein levels will definitely provide us useful information. Protein levels 
could be detected in the serum, lung or liver lavage fluid. A labmate has already analyzed the 
cytokine protein expression in the liver tissue samples. A similar result was obtained at 
protein level in respect of mRNA level that increased cytokine was detected in KO mice vs 
WT. In these early studies the measured levels were low and the difference between KO and 
WT were very close to being statistically significant. But more samples need to be measured. 
The protein level measurement could be done either by ELISA or Lumilex, which are 
frequently used methods. Both these methods are very sensitive and highly specific.  
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In addition to Utc knockouts, the Utc over-expressing (OX) mice are currently being  
bred in the lab now. The breeding is under way and animals are expected to be ready very 
soon. After the OX animals are available, they could be added in the study. The Utc over-
expressing mice could be treated in parallel with the Utc KO mice. The two groups of mice 
should provide a prefect comparison, such as the cytokine expression in the OX mice is 
expected to be lower than their WT littermates opposite to the results got from KO mice.  
 
We could also try to ectopically deliver Utc to KO mice after more convincing data  
are collected for the conditions when the greatest difference is observed in their response to 
LPS. If Utc is the true factor that causes the cytokine increase found in the KO mice or that 
causes the abnormal behavior observed for older KO mice, the delivery of Utc should be able 
to either reduce the increased cytokine expression or rescue the sick phenotype. Similar 
experiments could also be done in vitro with cell lines.    
   
 
 
 
 
 
 
 
 
 
  
63 
APPENDIX 
 
This part of work was done in my first year in the lab. We were interested in knowing  
the endogenous ligand(s) of Utc. Arachidonic acid was a promising candidate because it was 
reported to bind the chicken Lcn2 protein EX-FABP (Cancedda, Malpeli et al. 1996). In 
addition, arachidonic acid and its metabolites, such as prostaglandins, thromboxanes and 
leukotrienes, are well known to be involved in a variety of biological processes including 
inflammation, signaling transduction, chemotaxis, cell proliferation, differentiation and 
apoptosis (Karim, Habib et al. 1996; Kim and Kim 1997; Ghosh and Myers 1998; Williams, 
Leaver et al. 1998). If arachidonic acid is the true ligand of Lcn2, this information might shed 
light on why Lcn2 has been found associated with various phenomena, such as apoptosis 
(Devireddy, Teodoro et al. 2001; Devireddy, Gazin et al. 2005), tumor progression (Yan, 
Borregaard et al. 2001) or tumor suppression (Lee, Lee et al. 2006), sperm maturation and 
fertility (Chu, Lee et al. 2000) or renal injury rescue (Yang, Mori et al. 2003).  
 
To test our hypothesis that Utc binds arachidonic acid, three his-tagged Lcn2 proteins,  
his-Utc, his-NGAL and his-EXFABP, were purified using Ni-NTA system. Recombinant 
enterokinase was used to remove the his-tag. After enterokinase treatment, only 50% of 
NGAL and EX-FABP were recovered. Utc was completely lost during this process. To be 
consistent, the all three his-tagged proteins were used in arachidonic acid binding assay. 
Simultaneously, an ELISA was developed to measure the Lcn2 protein concentration. The 
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ELISA will be used to measure Utc concentration in the serum and in the lung lavage fluid 
from LPS treated mice.  
 
MATERIALS AND METHODS 
Bacterial recombinant his-tagged protein preparation: XL-1 blue bacteria  
containing the pTrcHisUtc2 plasmid, pTricHisNGAL plasmid or pcEXFABP/pTrcHis 
/EMW1 plasmid were separately inoculated into 20 ml of LB-broth (10 g/L tryptone, 5 g/L 
yeast extract and 10 g/L NaCl) with 50 µg/ml ampicillin at 37 oC, growing overnight with 
shaking. The next day, the cultures were inoculated in 1 L superbroth (32 g/L tryptone, 20 
g/L yeast extract, 5 g/L NaCl and 0.005 M NaOH) with 50 µg/ml ampicillin and grew until 
A600 reached 0.7 to 0.9. 1 mM IPTG was added to induce protein expression and the cells 
were incubated for an additional 5 h at 37oC. The cells were harvested by centrifugation at 
4oC, 4000×g for 20 min. The cell pellet was resuspended in lysis buffer (1 ml/100 ml cell 
culture). The cell suspension was rapidly frozen in about one liter of liquid nitrogen and 
stored at -80oC. The frozen cell suspension was thawed and supplemented with 1 mM PMSF, 
1 mg/ml lysozyme, 5 µg/ml DNAse I per gram of cell pellet. The mixture was brought to a 
final volume of 10 ml with lysis buffer. The tubes were incubated on ice for 30 min and the 
cells were disrupted using a vortex machine to mix vigorously for 30 seconds followed by 
incubating 3 min on ice. The vortex and 3 min rest were repeated for a total of five times. 
The following steps were then performed with the samples at 4oC: The lysate was centrifuged 
at 10,000×g for 20 min and supernatant was collected. 0.5 to 1 ml of 50% Ni-NTA resin 
slurry was equilibrated in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) by 
resuspending 3 times and spinning out the pellet. The washed resin was added to the bacterial 
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supernatant and mixed by inversion for 1 h. The mixture was loaded onto a narrow pore 
column (Poly-Prep Chromatography column, Bio-Rad) and the resin was allowed to settle. 
After 30 min, the column was opened, the flow through was collected, then the column was 
washed with cold lysis buffer until the A280 of the effluent was less than 0.01. The resin was 
washed with cold wash buffer (50 mM NaH2PO4, 300 mM NaCl, pH 6.0) until the A280 of the 
effluent was less than 0.01. The protein was then eluted with elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 4.5) and several fractions were collected. The purified protein 
was concentrated in a dialysis bag to a final volume of 1 to 2 ml using Aquacide II 
(Calbiochem). The protein was dialyzed at 4oC against 1000 fold volume of PBS buffer (137 
mM NaCl, 2.7 mM KCl, 10 mM Na2PH4, 1.8 mM KH2PO4, pH 7.4) with one change and 
stored at -80oC until use.  
 
Enterokinase cleavage of his-tag protein: The recombinant enterokinase (rEK)  
purchased from Novagen recognized the identical cleavage site (AspAspAspAspLys↓) as the 
native enzyme. Because each target protein presents the cleavage site somewhat differently, 
several rEK concentrations (from 0.003 U/µl to 0.03 U/µl), temperatures (4oC, 15oC, 25oC, 
37oC) and incubation time courses (2 h, 5 h, 8 h, 20 h, 22 h, 25 h) were tested for each 
protein to optimize specificity and efficiency of cleavage. First was the small scale 
optimization: rEK was serially diluted in rEK Dilution/Storage buffer (20 mM Tris -HCl pH 
7.4, 200 mM NaCl, 2 mM CaCl2, and 50% glycerol). rEK Cleavage/Capture buffer (20 mM 
Tris-HCl pH 7.4, 50 mM NaCl, 2 mM CaCl2), 0.3 µg/µl target protein, and 0.003 U/µl to 
0.03 U/µl rEK were assembled in a tube. Reactions were incubated at different temperatures 
for various times from 2 to 25 h. The cleavage extent of recombinant proteins in the samples 
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was determined by SDS-PAGE (sodium dodecyl sulfate – polyacrylamide gel electrophoresis, 
15% resolving gel, 5% stacking gel). A 48 kDa protein provided by Novagen was used as 
positive control. It was cleaved by rEK into two proteolytic fragments of 32 kDa and 16 kDa. 
Once a satisfactory condition was found for protein cleavage by rEK, the reaction was 
scaled-up. After the cleavage reaction, the rEK was removed by EKapture Agarose (50% 
slurry in phosphate buffer, pH 7.3, 0.5 M NaCl. 0.02% Thimerosal). The appropriate 
EKapture agarose was used based on the amount of rEK used in the cleavage reaction (2 
units rEK per 50 µl slurry bed volume). The EKapture agarose was equilibrated in rEK 
Cleavage/Capture buffer by spin gel filtration as follows: the entire cleavage reaction and the 
prepared agarose were gently mixed to resuspend the agarose. The mixture was transferred to 
a spin-filter and incubated at room temperature for 5 min. The reaction was centrifuged at 
1000×g for 5 min to remove the agarose. The rEK was bound to the agarose and retained in 
the cup of the spin-filter. The cleaved protein flowed into the filtrate tube during 
centrifugation. The protein was concentrated and dialyzed against PBS as needed.       
 
Arachidonic acid binding assay: EX-FABP was used as positive control in this  
assay based on a publication that EX-FABP binds to arachidonic acid (Cancedda, Malpeli et 
al. 1996). Tritium (3H) radiolabelled arachidonic acid (hot AA) and non-radiolabelled 
arachidonic acid (cold AA) was mixed to obtain AAmix. The ratio of hot AA and cold AA 
was varied to obtain different specific activities (mCi/mmol). Serial dilutions of the test 
proteins were made. Proteins of different concentrations were mixed with AAmix in 
siliconized microcentrifuge tubes for 10 seconds with hand shaking, then mixed by end-over-
end rotation for 30 min at 25oC (250 µl volume). The tubes were then chilled on ice for 10 
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min. The lipidex-1000 was washed 3 times with PBS at 4oC. PBS-washed 50% lipidex-1000 
slurry (200 µl) was added to protein and AAmix mixture. The tubes were hand shaken for 10 
seconds, and then mixed by inversion for 10 min at 4oC. The tubes were centrifuged at 
6000×g for 5 min at 4oC. 300 µl of supernatant was transferred into a scintillation vial 
containing 5 ml scintillation liquid. The radioactivity was counted using a scintillation 
spectrometer. The AAmix-only (background) and AAmix plus lipidex-1000 without protein 
addition (blank control) were counted at the same time.  
 
ELISA: NUNC Maxisorp 96 well ELISA plates were coated with 100 µl/well of  
antigen (his-Utc, his-EXFABP or his-NGAL) in coating buffer (137 mM NaCl, 2.68 mM 
KCl, 1.76 mM KH2PO4, and 5.98 mM Na2HPO4). Each plate was sealed and incubated 
overnight at 4oC then incubated at room temperature for 1 h. The coating solution was 
aspirated from the wells and the wells were washed five times with 300 µl/well of wash 
buffer (0.05% Tween-20, 137 mM NaCl, 10.1 mM Na2HPO4, 1.47 mM KH2PO4, and 2.68 
mM KCl). The plate was then inverted on absorbent paper to remove residual buffer and 200 
µl/well of blocking buffer was added (1% BSA, 137 mM NaCl, 10.1 mM Na2HPO4, 1.47 
mM KH2PO4, and 2.68 mM KCl). The plate was sealed again and incubated at room 
temperature for 1 h. The blocking buffer was aspirated from the wells and washed five times 
with 300 µl/well of wash buffer and 100 µl/well primary antibodies (Utc antiserum of 
optimal dilution in blocking buffer) was added. The plate was sealed and incubated at room 
temperature for 1 h. The antibodies were aspirated from the wells and the wells were washed 
five times with 300 µl/well of wash buffer. 100 µl/well secondary antibodies (goat anti-rabbit 
IgG-HRP of optimal dilution in blocking buffer) were added. The plate was sealed and 
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incubated at room temperature for 1 h. The secondary antibodies were aspirated from the 
wells and the wells were washed seven times with 300 µl/well of wash buffer with the last 
wash left on the wells to soak for 5 min then aspirated. 100 µl/well TMB 
(tetramethylbenzidine) substrate solution was added to each well and the plate was incubated 
at room temperature for 15 min. 50 µl of 2 M H2SO4 was then added to each well to stop the 
reaction. The plate was read (Universal Plate Reader EL800, Bio-Tek instruments, Inc.) at 
450 nM. The absorption values at 570 nM were subtracted from those at 450 nM and the data 
was analyzed. In each ELISA experiment, controls included wells in which the primary 
antibody, secondary antibody or substrate were omitted. Primary antibody dilutions from 
1/100 to 1/500000 and secondary antibody dilutions of 1/5000, 1/10000 and 1/50000 were 
tested to optimize ELISA conditions. Finally 1/10000 was chosen to be the optimal dilutions 
for both primary and secondary antibodies and linear regression equations were calculated 
for his-Utc, his-EXFABP and his-NGAL under the optimized conditions.  
 
RESULTS AND DISCUSSION 
Proteins were eluted in elution buffer and 3 to 5 eluted fractions were collected from  
the Ni-NTA column. No proteins were eluted in either lysis buffer or wash buffer. Usually 
milligram levels of proteins could be obtained form 1 liter of bacterial culture medium. The 
24 kDa his-Utc, 25 kDa his-NGAL and 21 kDa his-EXFABP were purified using Ni-NTA 
column chromatography (Fig. 16).       
 
Recombinant enterokinase was used to remove the his-tag from proteins to reduce the  
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possibility that his-tag might interfere with the arachidonic acid binding assay. Different rEK 
vs. protein ratios, reaction incubation time courses and temperatures were optimized for his-
NGAL (Fig 17A, Fig. 17B), his-Utc and his-EXFABP (data not shown) according to method 
description. For his-Utc and his-EXFABP, the final optimized parameters were the same: 
0.4U rEK, 25oC and 8 h. For his-NGAL, the optimal parameters were: 0.8U rEK, 37oC and 
20 h. The his-tags of his-EXFABP and his-NGAL could be completely cut by rEK, but only 
50% of the EX-FABP and NGAL fusion proteins could be recovered after the rEK capture 
step. For his-Utc, the maximal cleaved product was about 50% of the total, but the remaining 
half was completely lost during the rEK capture step. To keep consistent, the three his-tagged 
proteins were used in the arachidonic acid binding assay described below.  
 
His-EXFABP was used as positive control in this assay based on the report that it was  
bound to arachidonic acid (Cancedda, Malpeli et al. 1996). Lysozyme was used as negative 
control because it lacks arachidonic acid binding ability. Lipidex 1000 is lipophilic gel that 
specifically binds hydrophobic molecules. It was used in the assay to separate the protein-
bound arachidonic acid and the solution free arachidonic acid (Vork, Glatz et al. 1990; 
Cancedda, Malpeli et al. 1996). The binding activities were tested by using either a constant 
3H-arachidonic acid concentration while varying the protein concentrations or by using a 
constant protein concentration while varying the 3H-arachidonic acid concentrations (6.0, 0.6, 
0.06, 0.006, 0.0006 Ci/mmol). Generally, his-EXFABP always displayed arachidonic acid 
binding ability but not his-Utc, his-NGAL and lysozyme (data not shown). Fig. 18 shows 
some representative results obtained when using a constant arachidonic acid concentration 
while varying protein concentrations. His-EXFABP demonstrated apparent binding activity. 
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Bound arachidonic acid increased with increasing protein concentrations and at higher 
protein concentrations, the amount of the bound arachidonic acid approached a plateau phase. 
However, his-Utc and his-NGAL shared similar binding trends as lysozyme and no binding 
activity was observed. Similar results were observed when constant protein concentration 
while changing arachidonic acid concentrations (data not shown).  
 
An ELISA was developed to determine the amount of Utc in biological samples, for  
example, the sera or lung lavage fluid from LPS-treated mice, or the recombinant proteins 
from bacterial preparations. A Utc primary antibody was used in the ELISA experiment. 
Firstly, the Utc primary antibody concentration was optimized: 1/100, 1/500, 1/1000, 1/5000, 
1/10000, 1/50000, 1/100000 and 1/500000 dilutions were tested with Utc concentrations 
ranging from 5 pg/ml to 5 µg/ml. The secondary antibody dilution was constant at 1/10000 in 
the primary antibody optimization. Based upon the color development and data analysis, 
1/5000, 1/10000 and 1/50000 Utc dilutions were chosen to be further optimized (data not 
shown). Secondly, the secondary goat anti-rabbit IgG-HRP antibody was tested at 1/5000 and 
1/10000 dilutions when the primary antibody was at 1/5000, 1/10000 and 1/50000 dilutions 
respectively (data not shown). Finally based on the data analysis, both optimal primary 
antibody and secondary antibody dilutions were 1/10000. Wells lacking substrate TMB, 
primary antibody or secondary antibody addition were used as controls throughout the 
experiments. The Utc antibody was also used to detect his-EXFABP and his-NGAL proteins 
to see if it was specific for Utc or it had cross-species recognition capability. One result using 
optimized primary and secondary antibody dilutions at 1/10000 is shown in Fig. 19. Utc 
antibody could detect Utc very well. When his-Utc concentration was between 16 and 125 
  
71 
µg/ml, the R2 value of standard curve was 0.993. The R2 value of his-EXFABP standard 
curve was 0.9954, but all y axis values were below background (lower than the lowest y 
value of his-Utc). Similarly, the values from his-NGAL were almost below background and 
R2 value was 0.843. In summary, the Utc primary antibody is highly species specific and 
recognizes Utc very well but not human and chicken proteins.   
 
From Fig.16, we can see Ni-NTA is a very efficient protein purification system. Even  
though no obvious difference in protein components was observed between the lysate and 
flow through, purified his-tagged proteins were clearly seen in the elution fractions.  
 
During his-tag cleavage with enterokinase, the protein loss was firstly attributed to  
the protein binding to the membrane of the spin filter. Buffer conditions were changed by 
adding Triton X-100 or increasing the salt concentration. But neither change increased the 
protein yield. Using a lab-made phosphate buffer instead of company supplied buffer might 
be another way to try based on the suggestion from a lab member. She was doing rEK 
cleavage for another his-tagged protein and had a lot of protein loss using the company-
supplied buffer at the beginning. After she switched to her own phosphate buffer preparation, 
she got almost 100% recovery of the protein. The his-tag is present at the N-terminal of the 
three Lcn2 proteins and the N-terminal is not likely to be involved in the ligand binding, 
which mainly relies on the pocket structure formed by eight anti-parallel β-sheets. It was 
assumed that his-tag wouldn’t interfere with the arachidonic acid binding. Therefore the three 
his-tagged proteins were used further in the binding assay.      
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His-Utc showed an apparent binding like curve in the first experiment of the studies,  
but this activity was lost in subsequent experiments. It was postulated that the binding 
activity loss might be attributed to the freeze and thaw cycles of protein storage and 
utilization.  Freshly made proteins (his-Utc and his-NGAL) were the tested, but the binding 
phenomenon could not be repeated.  
 
Another possible explanation for the inconstant binding results was that binding is  
affected by protein post-translational modification. It was reported that the recombinant rat 
Lcn2 protein, NRL, cannot bind fatty acids although this binding was detected for 
recombinant chicken protein, EX-FABP (Cancedda, Malpeli et al. 1996; Zerega, Cermelli et 
al. 2000). Cancedda et al. reported that the native NRL protein from their lab or from rat 
mammary carcinomas always shows a slower electrophoretic mobility with respect to the 
recombinant NRL. The NRL protein in neu tumors had various larger molecular weights than 
the recombinant protein (Cancedda, Malpeli et al. 1996). The same difference was observed 
for native NGAL from tumor samples of human breast carcinomas with respect to the 
recombinant NGAL (Stoesz, Friedl et al. 1998). All these suggest a substantial 
posttranslational modification, most likely the glycosylation (Davis, Tabatabai et al. 1991; 
Cancedda, Malpeli et al. 1996; Stoesz, Friedl et al. 1998). The proteins used in our 
experiments were all bacteria expressed recombinant proteins. To further test the hypothesis 
that Lcn2 binds arachidonic acid, mammalian proteins should be used. 
 
Our Utc antibody is highly species specific. It doesn’t recognize NGAL or EX-FABP  
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based on the ELISA results. For the analysis, the original ELISA data were log transformed 
and the transformed data was used to plot the standard curve. This was done because log 
transformed data provides a better linear correlation. Although the ELISA for Utc 
demonstrated a good linear regression curve for which R2 was 0.993, the protein testing 
range fit the curve was only from 16 µg/ml to 125 µg/ml.  This is not a broad range. Further 
optimization could be done to extend the range by testing more secondary antibody dilutions 
or using more combinations of primary and secondary antibodies at different dilutions.  
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FIGURES 
 
FIGURE 1. Unfold structure of lipocalins. (Reprinted from (Flower, North et al. 2000), 
Copyright (2000), with permission from Elsevier) 
 
The nine antiparallel β-sheets are shown as arrows and labelled A-I. The C-terminal α-helix 
A1 and N-terminal 310 like helix are also marked. Connecting loops are shown as solid lines 
and labeled L1-L7. A pair of dotted lines indicates the hydrogen-bonded connection of two 
strands. One end of the lipocalin β-barrel has four loops (L1, L3, L5, and L7); the opening of 
the internal ligand-binding site is here and so is called the open end of the molecule. The 
other end has three β-hairpin loops (L2, L4 and L6); the N-terminal polypeptide chain 
crosses this end of the barrel to enter strand A via a conserved 310 helix closing this end of 
the barrel: the closed end of the molecule. Those parts that form the three main structurally, 
and sequence conserved regions (SCRs) of the fold (SCRl, SCR2, and SCR3) are marked as 
heavy boxes. SCR3 corresponds closely with the sequence conserved region rather than the 
structurally conserved region.  
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FIGURE 2. Crystal structure of NGAL. (Reprinted from (Goetz, Holmes et al. 2002), 
Copyright (2002), with permission from Elsevier) 
A.  Ribbon representation of the NGAL crystal structure (Helices, yellow; β-strands, 
green; loop, blue). 
 
B. Electrostatic potential mapping of NGAL surface. (blue, positive; red, negative) 
Ligand (catecholate-type siderophore) is displayed as stick representation. Three binding 
sites between ligand and NGAL are indicated. 
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FIGURE 3. LPS MyD88-dependent signaling pathway.  
In the cytosol, LPS first binds to LBP, the complex then transfers LPS to CD14 on the 
surface of the cell membrane. Once bound to LPS, CD14 facilitates the interaction of TLR4 
and MD-2, which causes TLR4 dimerization. The intracellular signal is triggered by 
activation of the TIR (Toll/IL-1R) domain of TLR4, which interacts with adaptor protein 
MyD88 though its TIR domain. MyD88 then activates IRAK, which activates TRAF6 
through phosphorylation. TRAF6 in turn activates the IκB kinase (IκK) dimer, IκK 
phosphorylates IκB, which forms a complex with NF-κB initially in the cytoplasm. The 
phosphorylation of IκB makes it dissociate from NF-κB and undergo ubiquitination and 
degradation by proteasome. The transcription factor NF-κB is free to go into the nucleus to 
bind the κB site at the target gene promoter region to turn on the NF-κB responsive gene 
expression, such as pro-inflammatory cytokines, chemokines and adhesion molecules. 
(Picture is adapted from http://www.sipage.ngfn.de/images/TLR-Pathway.jpg. Trinad 
Chakraborty, Justus Liebig University, Giessen).  
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FIGURE 4. Mouse genomic status test.  
 
Tail samples of 4712.11 to 4712.20 pups (The integer part of mouse number is the breeding 
number to indicate the mouse generation, the number after the decimal is the pup number. 
All pups in a single generation are included in the number series) were used for testing. NC, 
the negative control from a wild type genome DNA 4161 provided by Wei Zhao. M, the 
100bp DNA ladder plus marker. Either 528bp or 283bp amplicons or both were amplified 
from these mouse tails.  
 
Fig. 4 
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FIGURE 5. Cytokine primer pairs test.  
 
A. TNF-α primer pair test. 200 nM TNF-α primers 2501/2502 were used. Spleen cDNAs 
from m227.3 (0.4 mg/kg of LPS treated 8-week old KO), m230, m231, m234 and m235 (0.4 
mg/kg of LPS treated 7-week old normal Balb/c mice) were used as templates. SP after 
mouse number is an abbreviation for spleen. NTC, the no template control with same primer 
concentration added as for the cDNA samples. No amplicons were observed for this control. 
M, the low molecular weight DNA ladder marker (starting at 25bp with 25bp, 50bp, 150bp 
and 266bp increments sequentially). 175bp TNF-α fragment was amplified from all cDNA 
samples. 
 
B. IL-1β primer pair test. 200 nM IL-1β primers 2503/2504 were used. The same templates 
were used as in A. No PCR products were seen in NTC except primer dimers. 152bp IL-1β 
fragment was amplified from all tested cDNA samples.   
 
C. TNF-α, IL-1β and IL-6 primer pair test. 200 nM TNF-α primer pair 2501/2502, IL-1β 
primer pair 2503/2504 and IL-6 primer pair 2505/2506 were used. cDNA from LPS-
stimulated mouse primary spleen cells was used as a template. The 141bp IL-6 amplicon is 
indicated by the arrow pointing out from the left side of image. Except for the marker lane, 
the right three lanes are duplicate reactions of the left three lanes. The correct TNF-α, IL-1β 
and IL-6 fragments were successfully detected.   
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Fig. 5A 
 
Fig. 5B 
 
Fig. 5C 
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FIGURE 6. Cytokine and cyclophilin PCR optimization.  
 
A. TNF-α, IL-1β and IL-6 primer concentration optimization. 200, 400 and 800 nM 
primer concentrations were tested when Mg2+ was constant at 1.5 mM. m230SP (0.4 mg/kg 
of LPS treated 7-week old normal Balb/c mouse) cDNA was used as a template for TNF-α 
and IL-1β. LPS-stimulated mouse primary spleen cell cDNA (SP/LPS) was used as a 
template for IL-6. The no template controls (NTC) included either the IL-1β or the IL-6 
primers at 400 nM concentration. M, low molecular DNA ladder marker. Brighter bands 
were found at higher primer concentrations.  
 
B/C. TNF-α, IL-1β and IL-6 Mg2+ concentration optimization. 400 and 800 nM primer 
concentrations were used. 1.5, 3.0 and 6.0 mM Mg2+ concentrations were tested. No PCR 
products were amplified in the NTC. Mg2+ concentration within the testing range had little 
influence on PCR amplification.   
 
D. TNF-α, IL-1β and IL-6 optimal parameter confirmation. 200 nM, 400 nM and 800 nM 
primer concentrations were tested when Mg2+ was constant at 1.5 mM. Non-LPS stimulated 
primary spleen cell cDNA (SP/non-LPS) was used as a template for TNF-α and IL-1β cDNA 
amplification. LPS-stimulated spleen cell cDNA (SP/LPS) was used as a template for IL-6 
cDNA amplification. No amplicon was found in the NTC. Brighter bands were seen at higher 
primer concentrations. At 800nM, brightest bands were observed. 
 
E. Cyclophilin primer concentration optimization. 1.5 mM Mg2+ concentration was used. 
cDNA from m235 spleen was used as a template. 200, 400 and 600 nM of 1030/1031 primer 
concentrations were tested. No amplicon was found in the NTC. Duplicate reactions were 
done for each primer concentration. The correct cyclophilin PCR products were observed at 
all testing concentrations.   
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Fig. 6A 
 
Fig. 6B 
 
Fig.6C 
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Fig. 6D 
 
      
Fig. 6E 
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FIGURE 7. Multiplexed RT-PCR and PAGE optimization. 
 
A. Loading volume optimization. A partial list of the multiplexed RT-PCR parameters is at 
the left side of the image. m235SP (0.4 mg/kg of LPS treated 7-week old normal Balb/c 
mouse) and LPS-stimulated primary spleen cell (from Zhiping Liu) cDNAs were used as 
templates. Radiolabelled cyclophilin, TNF-α, IL-1β and IL-6 were used as standards to 
indicate PCR amplicon locations. No amplicon was found in the NTC. Clear and well 
separated bands were seen after resolving the product of the two tested templates. Different 
loading volumes had little influence on band visualization and 2 µl was chosen for use in 
further experiments.  
   
B. Cyclophilin primer concentration optimization. 100 nM cyclophilin primer was used. 
m231SP (0.4 mg/kg of LPS treated 7-week old normal balb/c mouse) and m227.3SP (0.4 
mg/kg of LPS treated 8-week old KO) cDNAs were used as templates. No amplicon was 
found in the NTC. Less dark cyclophilin bands are observed compared with those observed 
in panel A. Clear and well separated bands were seen for these two samples.    
 
C. PCR cycle optimization. 20 and 30 PCR cycle numbers were tested. m255LG (0.4 mg/kg 
of LPS treated 7-week old KO) and m231SP (0.4 mg/kg of LPS treated 7-week old normal 
Balb/c mouse) cDNAs were used as templates. No amplicon was found in the NTC. At 20 
cycles, no any amplicon was observed. At 30 cycles, clear and well separated bands were 
seen. 
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Fig. 7A 
 
Fig. 7B 
 
Fig. 7C 
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FIGURE 8. Multiplexed RT-PCR and PAGE results.  
 
Panel A and B are two representative gel pictures. The numbers at the top and bottom of the 
gels are individual mouse numbers. Two radiolabelled standards were loaded for each batch. 
Cyclophilin and IL-1β were loaded with the first batch of samples. TNF-α and IL-6 were 
loaded with the second batch of samples. The amplicon of the four standards are circled and 
identified at the arrow pointing at the right side of the figures. The positions of the four PCR 
fragments from cDNA samples are identified on the left side of the gels. In panel A, all 
samples are from lung. In panel B, all samples are from liver except m231, which is from 
spleen.        
   
Fig. 8A 
 
  
86 
 
 
 
Fig. 8B 
 
 
 
 
 
 
  
87 
FIGURE 9. Regulation of TNF-α, IL-1β and IL-6 in KO and WT lung and liver by LPS 
from multiplexed RT-PCR analysis.  
 
A. TNF-α, IL-1β and IL-6 regulation in the lung. LPS/PBS cytokine ratios were first 
calculated for 0.4 mg/kg, 2 mg/kg and 4 mg/kg treatments. The normalized ratios of 2 and 4 
mg/kg vs 0.4 mg/kg were then plotted in the figure. Filled lines and symbols represent 
cytokine values from KO mice. Dash line and open symbols represent cytokine values from 
WT littermates. Significances were observed for all three cytokines at the horizontal 
comparisons at 4 mg/kg KO vs 0.4 mg/kg KO and at vertical comparisons at 4 mg/kg KO vs 
4 mg/kg WT.  
  
B. TNF-α, IL-1β and IL-6 regulation in the liver. (Same plotting method as A) 
Significances were observed for three cytokines at the horizontal comparisons at 4 mg/kg KO 
vs 0.4 mg/kg KO. No significance was observed at vertical comparisons.    
 
STATISTICAL ANALYSIS: Two types of comparisons are made for this group of data. One 
is horizontal comparison, in which LPS/PBS ratios of 2 mg/kg and 4 mg/kg treatment are 
compared to 0.4 mg/kg value within same genotype. Asterisks are placed above or below the 
symbols. The other is vertical comparison, in which KO vs WT is made at three dose 
treatments. Asterisks are placed at the right side pointed out by parentheses. * represents 
P<0.05, and ** represents P<0.01. The statistical values listed below figures are from SAS 
PROC GLM without multiple comparisons. If the significance is observed also in SAS 
PROC GLM Tukey-Kramer (TK) justified multiple comparisons, the asterisks are circled. 
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Fig. 9A 
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STATISTICAL ANALYSIS:  
Multiplexed RT-PCR_ Cytokine_Lung 
Ratio LPS/PBS (KO) LPS/PBS (WT) KO/WT (LPS) 
LPS dose (mg/kg) 0.4 2 4 0.4 2 4 0.4 2 4 
TNF-α/Cyc 1.00 0.36 9.96 1.00 0.25 0.56 1.00 1.4 17.8 
IL-1β/Cyc 1.00 1.19 19.84 1.00 0.82 0.93 1.00 1.4 21.3 
IL-6/Cyc 1.00 0.85 74.51 1.00 1.23 1.69 1.00 0.7 44.1 
 
Horizontal comparisons (vs. 0.4 mg/kg) Mean Diff. 95% CI P value 
TNF-α: 4 KO vs 0.4 KO 0.827360 (0.195490, 1.459231) P<0.01** 
IL-1β: 4 KO vs 0.4 KO 1.177560 (0.560117, 1.795004) P<0.01** 
IL-6: 4 KO vs 0.4 KO 1.610294 (0.824446, 2.396141) P<0.01** 
Vertical comparisons (WT vs KO) Mean Diff. 95% CI P value 
TNF-α: 4 KO vs 4 WT 0.801607 (0.141641, 1.461574) P<0.01** 
IL-1β: 4 KO vs 4 WT 0.827635 (0.182736, 1.472533) P<0.01** 
IL-6: 4 KO vs 4 WT 1.297586 (0.476795, 2.118377) P<0.01** 
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Fig. 9B 
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STATISTICAL ANALYSIS:  
Multiplexed RT-PCR_ Cytokine_Liver  
Ratio LPS/PBS (KO) LPS/PBS (WT) KO/WT (LPS) 
LPS dose (mg/kg) 0.4 2 4 0.4 2 4 0.4 2 4 
TNF-α/Cyc 1.00 1.62 5.10 1.00 0.19 0.72 1.00 8.6 7.1 
IL-1β/Cyc 1.00 1.83 5.07 1.00 0.77 1.11 1.00 2.4 4.6 
IL-6/Cyc 1.00 1.34 9.43 1.00 0.61 3.37 1.00 2.2 2.8 
 
Horizontal comparisons (vs. 0.4 mg/kg) Mean Diff. 95% CI P value 
TNF-α: 4 KO vs 0.4 KO 0.714848 (0.090068, 1.339629) P<0.05* 
IL-1β: 4 KO vs 0.4 KO 0.848831 (0.389868, 1.307794) P<0.01** 
IL-6: 4 KO vs 0.4 KO 1.104664 (0.422776, 1.786552) P<0.01** 
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FIGURE 10. Standard sample preparations for Real-time RT-PCR. 
 
A. GAPDH preparation. Three different primer concentrations, 200 nM, 400 nM and 800 
nM, were tested by using primer pair 1030/1031. M was 100bp DNA ladder marker. Correct 
GAPDH fragments were seen on the gel. At 800nM, faint primer dimers were found.  
 
B. Utc preparation. Primer pair 1095/1096 was used. Three different primer concentrations, 
200 nM, 400 nM and 800 nM, were tested. Correct Utc amplicons were observed on the gel. 
At 800 nM, some primer dimers formed.   
 
C. IL-6 preparation. Three primer concentrations, 200, 400 and 800 nM, were tested by 
using primer pair 2505/2506. Correct IL-6 fragments were seen on the gel. At 800 nM, some 
primer dimers were found. 
 
D and E: TNF-α preparation. Weak TNF-α fragments were seen on D. The bands were 
then cut and pooled together to extract DNA. Recovered DNA was used as templates in E. 
100nM and 400nM primers were tested. No template control (NTC) was run simultaneously, 
and no amplicons were found. An old TNF-α preparation was loaded on the E to verify if the 
new preparation migrated to the same location.  
 
F. Visualization of GAPDH, Utc, TNF-α and IL-6 standard stocks. Final pooled and 
concentrated DNAs of GAPDH, Utc, and TNF-α and IL-6 were visualized on F. Correct and 
bright bands were observed.  
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Fig. 10A 
 
 
Fig. 10B 
 
 
Fig. 10C 
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Fig. 10D 
 
Fig. 10E 
 
 
Fig. 10F 
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FIGURE 11. Utc regulation in WT lung and liver by LPS from real-time RT-PCR 
analysis.  
 
A. Data from all mice. Original data of PBS treatment and LPS treatments from lung and 
liver were plotted. Bars with different fillings represent different treatments. Above the error 
bar is written the treatment, PBS, 0.4 mg/kg, 2 mg/kg or 4 mg/kg of LPS. The number that 
follows in parentheses is the number of mice. Significance was observed at 4 mg/kg LPS in 
PBS vs PBS in the liver. No significance was observed in the lung.   
 
B. Data from younger mice. (Same plotting methods as in A) Two significances were 
observed in the liver. One is 2 mg/kg LPS in PBS vs PBS and the other is 4 mg/kg LPS in 
PBS vs PBS. No significance was observed in the lung. 
 
C. Data from older mice. Similar plotting method was used as in A except only the PBS and 
4 mg/kg of LPS in PBS treatment data are plotted. Although the apparent increase was 
observed at 4 mg/kg LPS in PBS vs PBS in both lung and liver, no significant differences 
were observed for either.  
 
STATISTICAL ANALYSIS: Comparisons between different LPS treatments vs PBS are 
made for the lung and liver data. Asterisks are placed above the horizontal bracket. * 
represents P<0.05, and ** represents P<0.01. The statistical values listed below the figures 
are from SAS PROC GLM without multiple comparisons. If the significance is observed also 
in SAS PROC GLM Tukey-Kramer (TK) justified multiple comparisons, the asterisks are 
circled. 
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Fig. 11A 
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STATISTICAL ANALYSIS: 
RT-PCR_Utc_All mice 
 PBS LPS 
LPS dose (mg/kg) 0 0.4 2 4 
Utc/GAPDH 1.55E-01 8.31E-02 3.92E-01 3.43E-01 Lung Normalized to PBS 1.00 0.54 2.53 2.21 
Utc/GAPDH 5.83E-03 1.12E-02 5.29E-02 2.60E-01 Liver Normalized to PBS 1.00 1.92 9.08 44.60 
 
Horizontal comparisons (vs. PBS) Mean Diff. 95% CI P value 
Liver: 4 WT vs PBS WT 1.029634 (0.405036, 1.654232) P<0.01** 
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Fig. 11B 
Utc regulation in WT by LPS_Younger mice 
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STATISTICAL ANALYSIS: 
RT-PCR_Utc_Younger mice 
 PBS LPS 
LPS dose (mg/kg) 0 0.4 2 4 
Utc/GAPDH 1.95E-01 8.31E-02 3.92E-01 2.36E-01 Lung Normalized to PBS 1.00 0.43 2.01 1.21 
Utc/GAPDH 5.97E-03 1.12E-02 5.29E-02 4.24E-02 Liver Normalized to PBS 1.00 1.88 8.87 7.10 
 
Horizontal comparisons (vs. PBS) Mean Diff. 95% CI P value 
Liver: 2 WT vs PBS WT 0.839967 (0.161534, 1.518400) P<0.05* 
Liver: 4 WT vs PBS WT 0.816825 (0.303978, 1.329673) P<0.01** 
 
 
 
  
96 
 
Fig. 11C 
Utc regulation in WT by LPS_Older mice (4 mg/kg)
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STATISTICAL ANALYSIS: 
RT-PCR_Utc _Older mice  
 PBS LPS 
LPS dose (mg/kg) 0 4 
Utc/GAPDH 8.82E-02 4.32E-01 Lung Normalized to PBS 1.00 4.90 
Utc/GAPDH 5.60E-03 4.16E-01 Liver Normalized to PBS 1.00 74.29 
Note: No significance was observed for this group of data. 
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FIGURE 12. TNF-α and IL-6 regulation in KO and WT lung and liver by LPS from 
real-time RT-PCR all mouse data. 
 
A. TNF-α and IL-6 regulation in the lung. Normalized ratios of three LPS dose treatments 
vs PBS (LPS/PBS) was plotted in the figure. Filled lines and symbols represent cytokine 
values from KO mice. Dash line and open symbols represent cytokine values from WT 
littermates. Significances were observed for both TNF-α and IL-6 at vertical comparison at 4 
mg/kg LPS in the KO vs 4 mg/kg LPS in the WT.  
 
B. TNF-α and IL-6 regulation in the liver. (Same plotting methods as in A) Significances 
were observed for both TNF-α and IL-6 at horizontal comparison at 4 KO vs PBS KO. And 
significance at vertical comparison was also observed for IL-6 at 4 mg/kg LPS in the KO vs 
4 mg/kg in the WT.  
 
STATISTICAL ANALYSIS: Two types of comparisons are made for this group of data. One 
is horizontal comparison, in which three LPS dose treatments are compared with PBS 
treatment within same genotype. Asterisks are placed above the symbols. The other is 
vertical comparison, in which KO vs WT is made at different treatments. Asterisks are placed 
at the right side pointed out by parentheses. * represents P<0.05, and ** represents P<0.01. 
The statistical values listed below figures are from SAS PROC GLM without multiple 
comparisons. If the significance is observed also in SAS PROC GLM Tukey-Kramer (TK) 
justified multiple comparisons, the asterisks are circled. 
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Fig. 12A 
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STATISTICAL ANALYSIS: 
RT-PCR_Lung cytokine_All mice 
 KO WT KO/WT (LPS) 
 PBS LPS PBS LPS PBS LPS 
LPS dose 
(mg/kg) 0 0.4 2 4 0 0.4 4 0 0.4 4 
N 5 6 2 9 8 2 12 / / / 
IL-6 
/GAPDH  
7.48E-
03 
1.09E-
02 
1.60E-
02 
1.88E-
01 
2.16E-
03 
2.95E-
03 
4.00E-
03 3.5 3.7 47 
Normalized 
to PBS 1.00 1.46 2.14  25.14 1.00 1.37 1.85 1.0 1.1 13.6 
TNF-α 
/GAPDH 
2.16E-
02 
1.30E-
02 
8.71E-
02 
8.26E-
02 
9.86E-
03 
8.04E-
03 
1.51E-
02 2.2 1.6 5.5 
Normalized 
to PBS 1.0 0.6 4.0 3.8 1.0 0.8 1.5 1.0 0.7 2.5 
Note: 2 mg/kg treatment value of WT was removed from calculation because of the only one available data 
caused unreliable analysis. N is the mouse number used for each treatment. “/” means non-applicable. 
 
Vertical comparisons (WT vs KO) Mean Diff. 95% CI P value 
TNF-α: 4 KO vs 4 WT 1.143713 (0.544248, 1.743178) P<0.01** 
IL-6: 4 KO vs 4 WT 2.074916 (1.080160, 3.069671) P<0.01** 
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Fig. 12B 
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STATISTICAL ANALYSIS: 
RT-PCR_Liver cytokine_All mice 
 KO WT KO/WT (LPS) 
 PBS LPS PBS LPS PBS LPS 
LPS dose 
(mg/kg) 0 0.4 2 4 0 0.4 4 0 0.4 4 
N 5 6 2 9 8 2 12 / / / 
IL-6 
/GAPDH  
5.92E-
05 
3.77E-
05 
9.08E-
05 
4.34E-
03 
1.77E-
04 
1.45E-
04 
1.64E-
04 0.3 0.3 26.5 
Normalized 
to PBS 1.00 0.64 1.53  73.31 1.00 0.82 0.93 1.0 0.8 80.2 
TNF-α 
/GAPDH 
1.68E-
04 
1.79E-
04 
2.50E-
04 
1.20E-
03 
6.94E-
04 
9.12E-
04 
6.42E-
04 0.2 0.2 2.0 
Normalized 
to PBS 1.0 1.1 1.5 7.1 1.0 1.3 0.9 1.0 0.8 8.2 
Note: Same legend as Fig. 9A. 
 
Horizontal comparisons (vs. PBS) Mean Diff. 95% CI P value 
TNF-α: 4 KO vs PBS KO 0.736853 (0.162193, 1.311514) P<0.05* 
IL-6: 4 KO vs PBS KO 1.149172 (0.221824, 2.076520) P<0.05* 
Vertical comparisons (WT vs KO) Mean Diff. 95% CI P value 
IL-6: 4 KO vs 4 WT 1.405852 (0.672719, 2.138985) P<0.01** 
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FIGURE 13. TNF-α and IL-6 regulation in KO and WT lung and liver by LPS from 
real-time RT-PCR younger mouse data. 
 
A. TNF-α and IL-6 regulation in the lung. Normalized ratios of the three LPS dose 
treatments vs PBS (LPS/PBS) are plotted in the figure. Filled lines and symbols represent 
cytokine values from KO mice. Dash line and open symbols represent cytokine values from 
WT littermates. No significance was observed at any comparisons.  
 
B. TNF-α and IL-6 regulation in the liver. (Same plotting methods as in A). No significant 
differences were observed at any comparisons. 
 
STATISTICAL ANALYSIS: Two types of comparisons are made for this group of data. One 
is horizontal comparison, in which the three LPS dose treatments are compared with PBS 
treatment within same genotype. Asterisks are placed above the symbols to represent level of 
statistical significance. The other is vertical comparison, in which KO vs WT is made at 
different treatments. Asterisks are placed at the right side pointed out by parentheses. * 
represents P<0.05, and ** represents P<0.01. The statistical values listed below figures are 
from SAS PROC GLM without multiple comparisons. If the significance is observed also in 
SAS PROC GLM Tukey-Kramer (TK) justified multiple comparisons, the asterisks are 
circled. 
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Fig. 13A 
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STATISTICAL ANALYSIS: 
RT-PCR_Lung cytokine_Younger mice 
 
KO WT KO/WT 
(LPS) 
 PBS LPS PBS LPS PBS LPS 
LPS dose 
(mg/kg) 0 0.4 2 4 0 0.4 4 0 0.4 4 
N 5 6 2 6 5 2 5 / / / 
IL-6 
/GAPDH  
7.48E-
03 
1.09E-
02 
1.60E-
02 
1.91E-
02 
3.03E-
03 
2.95E-
03 
6.31E-
03 2.5 3.7 3.0 
Normalized 
to PBS 1.00 1.46 2.14  2.55 1.00 0.97 2.09 1.0 1.5 1.3 
TNF-α 
/GAPDH 
2.16E-
02 
1.30E-
02 
8.71E-
02 
3.74E-
02 
1.18E-
02 
8.04E-
03 
1.65E-
02 1.8 1.6 2.3 
Normalized 
to PBS 1.0 0.6 4.0
a
  1.7 1.0 0.7 1.4 1.0 0.8 1.4 
Note: Same legend as Fig. 9A. No significance was observed for this group of data. Data “a” wasn’t plot in the 
Fig. 10A. 
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Fig. 13B 
LPS/PBS individual cytokine_Liver_Younger mice
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STATISTICAL ANALYSIS: 
RT-PCR_Liver cytokine_Younger mice 
 
KO WT KO/WT 
(LPS) 
 PBS LPS PBS LPS PBS LPS 
LPS dose 
(mg/kg) 0 0.4 2 4 0 0.4 4 0 0.4 4 
N 5 6 2 6 5 2 5 / / / 
IL-6 
/GAPDH  
5.92E-
05 
3.77E-
05 
9.08E-
05 
4.04E-
04 
2.49E-
04 
1.45E-
04 
3.19E-
04 0.2 0.3 1.3 
Normalized 
to PBS 1.00 0.64 1.53  6.82 1.00 0.58 1.28 1.0 1.1 5.3 
TNF-α 
/GAPDH 
1.68E-
04 
1.79E-
04 
2.50E-
04 
9.71E-
04 
4.63E-
04 
9.12E-
04 
2.73E-
04 0.4 0.2 3.6 
Normalized 
to PBS 1.0 1.1 1.5  5.8 1.0 2.0 0.6 1.0 0.6 9.9 
Note: Same legend as Fig. 9A. No significance was observed for this group of data.  
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FIGURE 14. TNF-α and IL-6 regulation in KO and WT lung and liver by LPS from 
real-time RT-PCR older mouse data. 
 
A. TNF-α and IL-6 regulation in the lung. Original data of TNF-α and IL-6 in KO and WT 
lung at 4 mg/kg of LPS treatment were plotted. Significance was observed for both TNF-α 
and IL-6 at KO vs WT.   
 
B. TNF-α and IL-6 regulation in the liver. (Same plotting methods as in A) Significance 
was observed for IL-6 at KO vs WT but not for TNF-α.  
 
STATISTICAL ANALYSIS: KO vs WT comparison was made for this group of data at 4 
mg/kg of LPS treatment. Asterisk(s) is placed above the horizontal bracket. * represents 
P<0.05, and ** represents P<0.01. The statistical values listed below figures are from SAS 
PROC GLM without multiple comparisons. If the significance is observed also in SAS 
PROC GLM Tukey-Kramer (TK) justified multiple comparisons, the asterisks are circled.   
 
STATISTICAL ANALYSIS: 
 Lung Liver 
 WT KO KO/WT WT KO KO/WT 
N 7 3 / 7 3 / 
IL-6 /GAPDH 2.36E-03 5.25E-01 222.46 5.40E-05 1.22E-02 225.93 
TNF-α 
/GAPDH 1.40E-02 1.58E-01 11.29 9.05E-04 1.58E-03 1.75 
Note: Same legend as Fig. 9A. 
 
KO vs WT (LPS=4 mg/kg) Mean Diff. 95% CI P value 
TNF-α (lung): 4 KO vs 4 WT 2.079036 (0.855446, 3.302626) P<0.01** 
IL-6 (lung): 4 KO vs 4 WT 4.215481 (2.170134, 6.260828) P<0.01** 
IL-6 (liver): 4 KO vs 4 WT 3.055893 (1.732373, 4.379413) P<0.01** 
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Fig. 14A 
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FIGURE 15. H & E stain. (All slides were under Dr. Ackermann’s review and taken at 40X 
resolution.)  
A. Liver control slide of m252-/-. m252 is a PBS-treated 7-week old KO. No remarkable 
lesions were observed.  
B Lung control slide of m252-/-. m252 is a PBS-treated 7-week old KO. No remarkable 
lesions were observed.  
C. Neutrophils in the liver slide of m256+/+. m256 is a 4 mg/kg of LPS treated 11-week 
old WT. Some Neutrophils were seen in the blood vessel and scored as 1. Some neutrophils 
are pointed out by arrows.  
D. Neutrophils in the lung slide of m256+/+. m256 is a 4 mg/kg of LPS treated 11-week 
old WT. Some neutrophils was seen around capillaries and scores as 1. Some neutrophils are 
pointed out by arrows. 
E. An aggregate of neutrophils in the lung slide of m259LG-/-. m259 is a 4 mg/kg of LPS 
treated 14-week old KO. This slide had that most neutrophils of all slides and displayed a 
neutrophil aggregation around a capillary that was scored as 2. The arrow and dashed circle 
highlight the location of some neutrophils.  
Fig. 15A 
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Fig. 15B 
 
Fig. 15C  
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Fig. 15D  
 
Fig. 15E 
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FIGURE 16. His-tagged Protein purification.  
 
Three his-tagged proteins, his-Utc, his-NGAL and his-EXFABP were purified using Ni-NTA 
column chromatography. The protein can be observed in the elution fractions. Lysate, the cell 
lysate before applying to Ni-NTA column. FT, flow through collected prior to washing the 
column. LB, lysis buffer collection. WB, wash buffer collection. E1, E2 and E3, three 
sequential eluted fractions. No target proteins were seen in flow through or wash fractions. 
The recombinant proteins only appeared after they were eluted with low pH buffer. The 
relative molecular mass of purified his-Utc was 24 kDa, of his-NGAL was 26 kDa, and of 
his-EXFABP was 21 kDa.  
 
Fig. 16 
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FIGURE 17. Enterokinase cleavage optimization for his-NGAL.  
 
A. Enzyme concentration and incubation time optimization. Five different rEK 
concentrations and four different incubation time courses were tested. After cleavage, his-
NGAL shifted from 25 kDa to 22 kDa. At 0.8U rEK and 20 h incubation, completed 
cleavage was achieved. NC, negative control without adding rEK. Arrow and dashed circle 
pointed to the optimal conditions.  
 
B. Temperature optimization. Three different temperatures were tested. Only at 37oC was 
complete cleavage achieved.  
 
Fig. 17A 
 
 
Fig. 17B  
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FIGURE 18. Arachidonic acid binding assay.  
 
Duplicates were done for each sample. The AA* (3H-labelled) final concentration was 1.67 
pM in this experiment and the specific activity was 0.06 Ci/mmol. His-EXFABP was used as 
positive control. Lysozyme was used as a negative control. Data were generated by 
subtracting an average background value and then averaging duplicate values. Protein 
concentrations, cpm values and standard deviations are listed in the table. No arachidonic 
acid binding activity was found for his-Utc and his-NGAL.  
  
   His-Utc His-NGAL His-EXFABP Lysozyme 
Conc.(nM) Cpm Std. Conc.(nM) Cpm Std. Conc.(nM) Cpm Std. Conc.(nM) Cpm Std. 
0.01 60 17 0.01 38 61 0.02 36 1 0.01 460 93 
0.03 126 2 0.04 86 35 0.07 92 32 0.04 451 64 
0.11 149 68 0.14 104 14 0.24 989 30 0.14 572 100 
0.34 85 116 0.42 70 48 0.73 2519 331 0.42 549 65 
1.14 11 89 1.41 φ 66 2.42 5724 125 1.39 392 18 
3.42 28 16 4.23 121 122 7.26 7443 258 4.17 477 133 
Note: Conc., protein concentration (nM); Std., standard deviation; Cpm, average count per minute from 
duplicates after subtracting the background that was 474 cpm in this experiment. Negative values are reported 
as φ. 
 
Fig. 18 
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FIGURE 19. Establishing an ELISA assay for his-Utc, his-NGAL and his-EXFBAP. 
 
Standard curves are shown for his-Utc, his-NGAL and his-EXFABP. Triplicates were done 
for all samples. Protein concentrations and optical density values at 450 nm subtract 570 nm 
were log transformed for linear regression analysis. Both primary antibody and secondary 
antibody dilutions were 1/10000 in this experiment. Original protein concentrations, OD 
values, logarithm transformed values and c.v. are listed in the table. Linear equations and 
trendlines for his-Utc, his-EXFABP and his-NGAL are shown in figure.    
Protein Conc. (ng/ml) Conc. (nM) Log10Conc. (nM) OD450-570nm Log10OD c.v. 
125 5.3 0.73 1.42 0.15 3% 
62.5 2.7 0.43 0.48 -0.32 3% 
31 1.3 0.12 0.21 -0.68 4% His-Utc 
16 0.7 -0.18 0.10 -1.01 1% 
500 19.5 1.29 0.26 -0.58 3% 
125 4.9 0.69 0.25 -0.61 2% 
31 1.2 0.09 0.20 -0.69 6% His-NGAL 
8 0.3 -0.52 0.11 -0.95 3% 
500 23 1.36 0.09 -1.06 2% 
125 5.8 0.76 0.07 -1.17 2% 
31 1.4 0.16 0.05 -1.31 2% 
His-
EXFABP 
8 0.4 -0.44 0.04 -1.43 3% 
 
Fig. 19 
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TABLES 
 
TABLE 1. Mouse intranasal administration record 
Mouse # Genotype Sex Age (week) Status Treatment Time 
m227.1 -/- M 8 Die (soon) 0.4 mg/kg 6h 
m227.2 -/- M 8 Die (soon) 0.4 mg/kg 6h 
m227.3 -/- M 8 Survive 0.4 mg/kg 6h 
m228 +/+ (NB) F 7 Survive PBS 6h 
m229 +/+ (NB) F 7 Survive  PBS  6h 
m230 +/+ (NB) F 7 Survive 0.4 mg/kg 6h 
m231 +/+ (NB) F 7 Survive 0.4 mg/kg 6h 
m232 +/+ (NB) M 7 Die (soon) PBS 6h 
m233 +/+ (NB) M 7 Survive PBS 6h 
m234 +/+ (NB) M 7 Survive 0.4 mg/kg 6h 
m235 +/+ (NB) M 7 Survive 0.4 mg/kg 6h 
m241 -/- M 25 Survive 0.4 mg/kg 6h 
m242 -/- M 25 Survive 0.4 mg/kg 6h 
m243 -/- M 15 Survive 0.4 mg/kg 6h 
m244 +/- M 25 Survive 0.4 mg/kg 6h 
m245 +/+ M 25 Survive 0.4 mg/kg 6h 
m246 -/- M 7 Survive PBS  6h 
m247 -/- M 7 Survive 0.4 mg/kg 6h 
m248 -/- M 7 Survive 0.4 mg/kg 6h 
m249 +/+ M 7 Survive PBS 6h 
m250 +/+ M 7 Survive 0.4 mg/kg 6h 
m251 +/+ M 7 Survive 0.4 mg/kg 6h 
m252 -/- M 7 Survive PBS 6h 
m253 -/- M 7 Survive 0.4 mg/kg 6h 
m254 -/- M 7 Survive 0.4 mg/kg 6h 
m255 -/- M 7 Survive 0.4 mg/kg 6h 
m256 +/+ M 11 Survive 4 mg/kg 6h 
m257 +/+ M 11 Survive 4 mg/kg 6h 
m258 -/- M 14 Survive 4 mg/kg 6h 
m259 -/- M 14 Die (6 h) 4 mg/kg 6h 
m260 -/- M 14 Survive 4 mg/kg 6h 
m261 -/- M 8 Survive NT 6h 
m262 -/- M 8 Survive NT 6h 
m263 +/+ M 8 Survive PBS  6h 
m264 +/+ M 8 Survive PBS 6h 
m265 +/+ M 8 Survive 2 mg/kg 6h 
m266 +/+ M 8 Die (6 h) 2 mg/kg 6h 
m267 -/- M 8 Survive PBS  6h 
m268 -/- M 8 Survive PBS  6h 
m269 -/- M 8 Survive 2 mg/kg 6h 
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TABLE 1. (continued) 
Mouse # Genotype Sex Age (week) Status Treatment Time 
m270 -/- M 8 Die (soon) 2 mg/kg 6h 
m271 +/+ M 11 Survive NT  6h 
m272 +/+ M 11 Survive NT  6h 
m273 +/+ M 11 Survive PBS  6h 
m274 +/+ M 11 Survive PBS  6h 
m275 -/- M 8 Survive NT 6h 
m276 -/- M 8 Survive PBS  6h 
m277 -/- M 8 Survive 4 mg/kg 6h 
m278 -/- M 8 Survive 4 mg/kg 6h 
m279 -/- M 8 Survive 4 mg/kg 6h 
m280 +/+ M 8 Survive NT  6h 
m281 +/+ M 8 Survive NT  6h 
m282 +/+ M 8 Survive 4 mg/kg 6h 
m283 +/+ M 8 Survive 4 mg/kg 6h 
m284 +/+ M 8 Survive 4 mg/kg 6h 
m312 +/+ M 8 Survive PBS (lung lavage) 6h 
m313 +/+ M 8 Survive PBS  6h 
m314 +/+ M 8 Survive 4 mg/kg 6h 
m315 +/+ M 8 Survive 4 mg/kg 6h 
m316 -/- M 8 Survive 4 mg/kg 6h 
m317 -/- M 8 Survive 4 mg/kg 6h 
m318 -/- M 8 Survive 4 mg/kg 6h 
mA5054 +/+ F 14 Survive 4 mg/kg 6h 
mA5055 +/+ F 14 Survive 4 mg/kg 6h 
mA5056 +/+ F 14 Survive 4 mg/kg 6h 
mA5057 +/+ F 14 Survive 4 mg/kg 6h 
mA5058 +/+ M 14 Survive PBS  6h 
mA5059 +/+ F 14 Survive 4 mg/kg 6h 
Note: 6 dead mice are gray highlighted. “Soon” means mice died immediately after CO2 anesthesia, “6 h” 
means mice died after 6 h treatment. “-/-” is Utc knockout, “+/+” is wild type littermate, “+/-“ is heterozygote. 
“NB” is Normal Balb/c mouse. “Lung lavage” means the mouse was lung lavaged immediately after sacrifice. 
“M” is male, “F” is female. “m” before numerical numbers in mouse # section means the animal species is 
mouse. NT is no treatment (mice were directly taken out of cage and sacrificed by CO2). PBS is endotoxin-free 
PBS treatment. 0.4 mg/kg, 2 mg/kg and 4 mg/kg indicate mice were treated with 0.4, 2 or 4 mg/kg of LPS.  
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TABLE 2. Lung and liver multiplexed RT-PCR data 
Lung Liver 
Sample Age (wks) 
Treatment 
(6h) TNF-a / Cyc 
IL-1β/ 
Cyc 
IL-6/ 
Cyc 
TNF-a 
/ Cyc 
IL-1β/ 
Cyc 
IL-6/ 
Cyc 
m228+/+  7 PBS 0.37  0.49  0.22  0.06  0.25  0.13  
m229+/+ 7 PBS 0.14  0.69  0.27  0.07  0.50  0.13  
m233+/+ 7 PBS 0.26  1.21  0.62  0.09  0.44  0.18  
m230+/+ 7 0.4 mg/kg 0.21  1.03  0.28  0.07  0.57  0.13  
m231+/+ 7 0.4 mg/kg 0.18  0.91  0.18  0.08  0.44  0.13  
m234+/+  7 0.4 mg/kg 0.21  1.05  0.25  0.07  0.42  0.09  
m235+/+ 7 0.4 mg/kg 0.15  0.70  0.13  0.09  0.53  0.13  
m261-/-  8 NT 0.43  0.62  1.09  0.20  0.71  1.52  
m262-/-  8 NT 0.18  0.16  0.23  0.41  1.10  1.89  
m275-/-  8 NT 7.72  19.65  77.75   4.88  5.10  35.84  
m246-/-  7 PBS 0.58  1.04  1.11  0.44  1.07  1.42  
m252-/-  7 PBS 0.13  0.33  0.43  0.67  0.64  0.81  
m267-/-  8 PBS 0.24 1.56  1.69  0.03  0.11  0.20  
m268-/-  8 PBS 0.23  1.00  1.43  0.09  0.19  0.17  
m276-/-  8 PBS 312.14   770.89   3892.76  0.18  0.31  1.45  
m227.3-/-  8 0.4 mg/kg 0.19  0.97  0.36  0.08  0.44  0.13  
m247-/-  8 0.4 mg/kg 0.48  0.68  0.76  0.64  1.69  2.43  
m248-/-  8 0.4 mg/kg 0.85  0.82  1.82  0.11  0.37  0.29  
m253-/-  7 0.4 mg/kg 0.20  0.33  0.43  0.06  0.17  0.18  
m254-/- 7 0.4 mg/kg 0.22  0.30  0.31  0.07  0.16  0.19  
m255-/- 7 0.4 mg/kg 0.24  0.35  0.28  0.06  0.11  0.15  
m269-/-  8 2 mg/kg 0.20  1.12  0.21  0.67  0.80  
m270-/-  8 2 mg/kg 0.06  0.25  
0.88  
0.24  0.34  1.12  0.71  
m258-/-  14 4 mg/kg 0.59  3.77  3.07  0.13  1.15  0.67  
m259-/-  14 4 mg/kg 1.34  3.98  13.74  0.61  1.36  3.70  
m260-/-  14 4 mg/kg 1.12  5.51  13.04  0.20  1.33  1.48  
m277-/- 8 4 mg/kg 11.41  33.70  173.42  0.59  4.05  5.78  
m278-/- 8 4 mg/kg -9.52   -34.41   -101.99  1.19  3.93  7.34  
m279-/-  8 4 mg/kg 3.63  10.08  42.62  2.48  3.08  12.82  
m271+/+  11 NT 0.68  2.95  2.60  3.05  4.21  18.58  
m272+/+  11 NT 0.99  1.89  8.85  1.17  3.64  4.39  
m280+/+  8 NT 0.09  0.56  0.99  0.65  0.85  4.64  
m281+/+  8 NT 0.23  0.29  0.59  0.51  1.12  3.45  
m249+/+  7 PBS 0.96  1.59  2.31  0.22  0.43  0.45  
m263+/+  8 PBS 0.04  0.24  0.59  0.30  0.99  1.15  
m264+/+  8 PBS 0.14  0.41  0.52  0.15  0.52  0.48  
m273+/+  11 PBS 2.61  4.50  15.79  3.63  9.59  18.99  
m274+/+  11 PBS 1.98  7.71  22.37  2.15  2.27  16.75  
m250+/+  7 0.4 mg/kg 0.66  1.31  1.08  0.80  1.32  1.69  
m251+/+  7 0.4 mg/kg 0.91  1.50  1.47  1.23  0.75  1.24  
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TABLE 2. (continued) 
Lung Liver 
Sample Age (wks) 
Treatment 
(6h) TNF-a / Cyc 
IL-1β/ 
Cyc 
IL-6/ 
Cyc 
TNF-a 
/ Cyc 
IL-1β/ 
Cyc 
IL-6/ 
Cyc 
m265+/+  8 2 mg/kg 0.05  0.15  0.37  0.09  0.39  0.49  
m266+/+  8 2 mg/kg 0.35  2.16  2.77  0.29  1.20  1.30  
m256+/+  11 4 mg/kg 0.29  1.94  0.60  0.04  0.34  0.23  
m257+/+  11 4 mg/kg 0.18  0.89  0.73  0.07  0.43  0.28  
m282+/+  8 4 mg/kg 0.11  0.45  0.14  1.50  2.09  8.19  
m283+/+  8 4 mg/kg 0.66  1.73  4.32  0.94  1.34  7.09  
m284+/+  8 4 mg/kg 0.95  1.52  4.99  1.08  1.56  8.88  
Note: Gray highlighted values in lung section were not used for final data analysis because of the either 
extremely high ratios or the negative ratios. Other abbreviations had same meanings as in table 1. 
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TABLE 3. Lung and Liver real-time RT-PCR data 
Lung  Liver  
Samples Age (wks) 
Treatment 
(6h) Utc/ GAPDH 
IL-6/ 
GAPDH 
TNF-a/ 
GAPDH 
Utc/ 
GAPDH 
IL-6/ 
GAPDH 
TNF-a/ 
GAPDH 
m261-/- 8 NT  N/A 2.00E-03 1.90E-02 N/A 4.94E-05 1.88E-04 
m262-/- 8 NT  N/A 1.26E-03 5.38E-03 N/A 2.50E-05 2.13E-04 
m275-/- 8 NT  N/A 9.10E-04 2.16E-02 N/A 1.17E-05 1.48E-04 
m246-/- 7 PBS N/A 1.96E-03 1.39E-02 N/A 3.76E-05 1.43E-04 
m252-/- 7 PBS N/A 5.97E-03 5.67E-03 N/A 8.40E-05 4.16E-04 
m267-/- 8 PBS N/A 1.35E-02 3.08E-02 N/A 6.19E-05 1.02E-04 
m268-/- 8 PBS N/A 1.20E-02 2.96E-02 N/A 9.50E-06 1.39E-05 
m276-/- 8 PBS N/A 3.98E-03 2.80E-02 N/A 1.03E-04 1.62E-04 
m227.3-/- 7 0.4 mg/kg N/A 2.65E-03 5.72E-03 N/A 1.50E-05 4.17E-05 
m247-/- 7 0.4 mg/kg N/A 2.88E-03 1.85E-02 N/A 9.79E-05 2.58E-04 
m248-/- 7 0.4 mg/kg N/A 2.70E-02 1.87E-02 N/A 2.88E-05 7.82E-05 
m253-/- 7 0.4 mg/kg N/A 2.42E-02 1.58E-02 N/A 3.89E-05 2.12E-04 
m254-/- 7 0.4 mg/kg N/A 3.12E-03 7.91E-03 N/A 1.78E-05 1.91E-04 
m255-/- 7 0.4 mg/kg N/A 5.30E-03 1.13E-02 N/A 2.77E-05 2.96E-04 
m269-/- 8 2 mg/kg  N/A 2.97E-02 1.60E-01 N/A 1.25E-04 3.38E-04 
m270-/- 8 2 mg/kg  N/A 2.26E-03 1.37E-02 N/A 5.68E-05 1.62E-04 
m258-/- 14 4 mg/kg  N/A 3.29E-01 1.55E-01 N/A 1.77E-02 2.69E-03 
m259-/- 14 4 mg/kg  N/A 3.11E-01 1.09E-01 N/A 4.02E-03 2.55E-04 
m260-/- 14 4 mg/kg  N/A 9.36E-01 2.11E-01 N/A 1.49E-02 1.78E-03 
m277-/- 8 4 mg/kg  N/A 1.50E-03 3.03E-02 N/A 6.29E-05 3.37E-04 
m278-/- 8 4 mg/kg  N/A 7.28E-03 7.78E-02 N/A 3.94E-05 7.51E-05 
m279-/- 8 4 mg/kg  N/A 2.12E-03 1.27E-02 N/A 3.02E-05 1.55E-04 
m316-/- 8 4 mg/kg N/A 2.11E-02 6.03E-02 N/A 2.59E-04 7.73E-04 
m317-/- 8 4 mg/kg N/A 5.40E-03 6.03E-03 N/A 5.97E-04 N/A 
m318-/- 8 4 mg/kg N/A 7.74E-02 N/A N/A 1.44E-03 3.52E-03 
m271+/+ 11 NT  5.99E-02 4.84E-04 9.92E-03 1.17E-03 5.44E-06 1.34E-04 
m272+/+ 11 NT  5.10E-02 4.19E-04 4.41E-03 4.03E-03 9.34E-06 6.11E-05 
m280+/+ 8 NT  6.73E-02 1.83E-02 1.67E-01 1.61E-03 2.59E-04 1.00E-04 
m281+/+ 8 NT  9.57E-02 1.57E-02 1.12E-01 1.45E-03 3.01E-04 1.74E-04 
m249+/+ 7 PBS 1.25E-01 4.84E-03 1.67E-02 7.97E-03 3.57E-04 9.53E-04 
m263+/+ 8 PBS 6.46E-02 3.81E-04 1.55E-03 8.40E-03 1.12E-04 2.73E-04 
m264+/+ 8 PBS  5.25E-01 5.38E-03 2.75E-02 5.56E-03 1.48E-04 9.70E-05 
m273+/+ 11 PBS 1.07E-01 7.04E-04 8.57E-03 7.64E-03 1.32E-04 5.56E-05 
m274+/+ 11 PBS 1.55E-01 1.41E-03 1.06E-02 6.54E-03 3.81E-05 2.72E-04 
m312+/+ 8 PBS 1.90E-01 1.74E-03 7.98E-03 1.25E-03 2.24E-05 1.77E-04 
m313+/+ 8 PBS 7.03E-02 2.79E-03 5.43E-03 6.64E-03 6.06E-04 8.13E-04 
m5058+/+ 14 PBS 2.47E-03 7.52E-06 5.11E-04 2.61E-03 4.02E-06 2.91E-03 
m250+/+ 7 0.4 mg/kg 6.23E-02 2.77E-04 4.14E-03 3.87E-03 2.10E-04 9.29E-04 
m251+/+ 7 0.4 mg/kg 1.04E-01 5.62E-03 1.19E-02 1.86E-02 8.08E-05 8.96E-04 
m265+/+ 8 2 mg/kg  3.25E-01 1.35E-03 1.06E-02 9.30E-02 3.66E-03 4.50E-05 
m266+/+ 8 2 mg/kg  4.59E-01 1.10E+00 1.61E-01 1.28E-02 1.26E-02 5.45E-04 
m256+/+ 11 4 mg/kg  2.33E+00 1.46E-02 8.95E-02 2.96E-01 1.63E-04 4.02E-04 
m257+/+ 11 4 mg/kg  1.81E-01 1.84E-03 5.43E-03 3.67E-01 1.54E-04 8.40E-05 
m282+/+ 8 4 mg/kg  2.83E-01 4.46E-03 1.06E-02 2.41E-02 6.99E-05 1.09E-04 
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TABLE 3. (continued) 
Lung  Liver  
Samples Age (wks) 
Treatment 
(6h) Utc/ GAPDH 
IL-6/ 
GAPDH 
TNF-a/ 
GAPDH 
Utc/ 
GAPDH 
IL-6/ 
GAPDH 
TNF-a/ 
GAPDH 
m283+/+ 8 4 mg/kg  2.63E-01 2.17E-03 2.98E-02 2.49E-02 2.32E-05 1.56E-04 
m284+/+ 8 4 mg/kg  3.65E-01 9.86E-03 1.74E-02 1.56E-02 2.08E-05 4.13E-05 
m314+/+ 8 4 mg/kg 9.58E-02 9.41E-03 1.09E-02 3.60E-02 1.13E-03 6.20E-04 
m315+/+ 8 4 mg/kg 1.75E-01 5.67E-03 1.41E-02 1.11E-01 3.47E-04 4.38E-04 
m5054+/+
 
14 4 mg/kg  6.49E-02 7.23E-06 4.70E-04 3.32E-01 3.55E-06 2.61E-04 
m5055+/+ 14 4 mg/kg 9.54E-04 1.03E-06 1.05E-04 8.63E-04 3.81E-07 1.25E-03 
m5056+/+ 14 4 mg/kg 8.35E-04 5.72E-07 2.47E-04 2.14E-02 2.13E-06 2.14E-03 
m5057+/+ 14 4 mg/kg 1.18E-02 3.22E-05 2.14E-03 1.88E+00 5.29E-05 1.21E-03 
m5059+/+ 14 4 mg/kg N/A 3.53E-06 4.20E-04 1.23E-02 1.22E-06 9.85E-04 
Note: “N/A” meant non applicable. Gray highlighted data was the only one that was not used for final data 
analysis because of its 1000 fold high value than its group member. Duplicates were done for all samples. Other 
abbreviations had same meanings as in Table 1. 
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TABLE 4. H & E stain record and scoring 
H & E stain Samples Genotype Age (wks) Treatment (6h) Liver Lung Vascular 
m261 -/- 8 NT  0 0 0 
m262 -/- 8 NT  0 0 0 
m275 -/- 8 NT  0 0 0 
m246 -/- 7 PBS 0 0 0 
m252 -/- 7 PBS 0 0 0 
m267 -/- 8 PBS 0 0 0 
m268 -/- 8 PBS 0 0 0 
m276 -/- 8 PBS 0 0 0 
m227.3 -/- 7 0.4 mg/kg N/A N/A N/A 
m247 -/- 7 0.4 mg/kg 0 0 0 
m248 -/- 7 0.4 mg/kg 0 0 E 
m253 -/- 7 0.4 mg/kg 0 0 0 
m254 -/- 7 0.4 mg/kg 0 0 0 
m255 -/- 7 0.4 mg/kg 0 0 0 
m269 -/- 8 2 mg/kg  0 0 0 
m270 -/- 8 2 mg/kg  0 0 0 
m258 -/- 14 4 mg/kg  1 2 0 
m259 -/- 14 4 mg/kg  0-1 2 0 
m260 -/- 14 4 mg/kg  0-1 1-2 0 
m277 -/- 8 4 mg/kg  0 1 0 
m278 -/- 8 4 mg/kg  0 0 0 
m279 -/- 8 4 mg/kg  0 0 0 
m316 -/- 8 4 mg/kg 0 0 0 
m317 -/- 8 4 mg/kg 0 0 0 
m318 -/- 8 4 mg/kg 0 0 0 
m271 +/+ 11 NT  0 0 0 
m272 +/+ 11 NT  0 0 0 
m280 +/+ 8 NT  0 0 0 
m281 +/+ 8 NT  0 0 0 
m249 +/+ 7 PBS 0 0 0 
m263 +/+ 8 PBS 0 1 0 
m264 +/+ 8 PBS  0 0 0 
m273 +/+ 11 PBS 0 0 0 
m274 +/+ 11 PBS 0 0 E (mild) 
m312 +/+ 8 PBS 0 0 E (mild) 
m313 +/+ 8 PBS 0 0 0 
m5058 +/+ 14 PBS 0 0 1 
m250 +/+ 7 0.4 mg/kg 0 0 0 
m251 +/+ 7 0.4 mg/kg 0 0 0 
m265 +/+ 8 2 mg/kg  0 0-1 0 
m266 +/+ 8 2 mg/kg  0 1 E 
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TABLE 4. (continued) 
H & E stain Samples Genotype Age (wks) Treatment (6h) Liver Lung Vascular 
m256 +/+ 11 4 mg/kg  1 1-2 1 
m257 +/+ 11 4 mg/kg  1 1 1 
m282 +/+ 8 4 mg/kg  0 0 1 
m283 +/+ 8 4 mg/kg  0 0 0 
m284 +/+ 8 4 mg/kg  0 0 1 
m314 +/+ 8 4 mg/kg 0 0 0 
m315 +/+ 8 4 mg/kg 0 0 0 
m5054
 
+/+ 14 4 mg/kg  0 0 1 
m5055 +/+ 14 4 mg/kg 0 0 1 
m5056 +/+ 14 4 mg/kg 0 0 1 
m5057 +/+ 14 4 mg/kg 0 0 1 
m5059 +/+ 14 4 mg/kg 0 0 1 
All slides were under Dr. Ackermann’s review and scoring. Scoring criteria is listed following the table.     
 
H & E stain scoring criteria: 
Liver Lung Vascular 
0 = no remarkable lesion 0 = no remarkable lesion 0 = no remarkable lesion 
1 = earliest detectable 
increase in neutrophils in 
blood vessels 
1 = earliest detectable 
increase in neutrophils in 
capillaries/septa/vessels 
2 = neutrophils in aggregates 
or margination in vessels 
2 = neutrophils in aggregates 
in the airways 
3 = neutrophil infiltration 
into the liver parenchyma 
3 = neutrophils filling 
alveolar lumens/airways 
1 = earliest detectable 
increase in eosinophilia 
(redness) of the vascular 
smooth muscle 
 
 
4 = extensive neutrophils 
involving >30% of the 
section 
E = edema around vessels 
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